System for enriching a bodily fluid with a gas

Information

  • Patent Grant
  • 6582387
  • Patent Number
    6,582,387
  • Date Filed
    Tuesday, March 20, 2001
    23 years ago
  • Date Issued
    Tuesday, June 24, 2003
    20 years ago
Abstract
A system utilizes an oxygenation device to generate a gas-enriched physiologic fluid and to combine it with a bodily fluid to create a gas-enriched bodily fluid. The oxygenation device may take the form of a disposable cartridge, which is placed within an enclosure. An electronic controller manages various aspects of the system, such as the production of gas-enriched fluids, flow rates, bubble detection, and automatic operation and shut down.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




The present invention relates generally to gas-enriched fluids and, more particularly, to a system that enriches a bodily fluid with a gas.




2. Background of the Related Art




This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention that are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.




Gas-enriched fluids are used in a wide variety of medical, commercial, and industrial applications. Depending upon the application, a particular type of fluid is enriched with a particular type of gas to produce a gas-enriched fluid having properties that are superior to the properties of either the gas or fluid alone for the given application. The techniques for delivering gas-enriched fluids also vary dramatically, again depending upon the particular type of application for which the gas-enriched fluid is to be used.




Many commercial and industrial applications exist. As one example, beverages may be purified with the addition of oxygen and carbonated with the addition of carbon dioxide. As another example, the purification of wastewater is enhanced by the addition of oxygen to facilitate aerobic biological degradation. As yet another example, in fire extinguishers, an inert gas, such as nitrogen, carbon dioxide, or argon, may be dissolved in water or another suitable fluid to produce a gas-enriched fluid that expands on impact to extinguish a fire.




While the commercial and industrial applications of gas-enriched fluids are relatively well known, gas-enriched fluids are continuing to make inroads in the healthcare industry. Oxygen therapies, for instance, are becoming more popular in many areas. A broad assortment of treatments involving oxygen, ozone, H


2


O


2


, and other active oxygen supplements has gained practitioners among virtually all medical specialties. Oxygen therapies have been utilized in the treatment of various diseases, including cancer, AIDS, and Alzheimer's. Ozone therapy, for instance, has been used to treat several million people in Europe for a variety of medical conditions including excema, gangrene, cancer, stroke, hepatitis, herpes, and AIDS. Such ozone therapies have become popular in Europe because they tend to accelerate the oxygen metabolism and stimulate the release of oxygen in the bloodstream.




Oxygen is a crucial nutrient for human cells. It produces energy for healthy cell activity and acts directly against foreign toxins in the body. Indeed, cell damage may result from oxygen depravation for even brief periods of time, and such cell damage can lead to organ dysfunction or failure. For example, heart attack and stroke victims experience blood flow obstructions or divergence that prevent oxygen in the blood from being delivered to the cells of vital tissues. Without oxygen, these tissues progressively deteriorate and, in severe cases, death may result from complete organ failure. However, even less severe cases can involve costly hospitalization, specialized treatments, and lengthy rehabilitation.




Blood oxygen levels may be described in terms of the concentration of oxygen that can be achieved in a saturated solution at a given partial pressure of oxygen (pO


2


). Typically, for arterial blood, normal oxygen levels, i.e., normoxia or normoxemia, range from 90 to 110 mmHg. Hypoxemic blood, i.e., hypoxemia, is arterial blood with a pO


2


less than 90 mmHg. Hyperoxemic blood, i.e., hyperoxemia or hyperoxia, is arterial blood with a pO


2


greater than 400 mmHg, but less than 760 mmHg. Hyperbaric blood is arterial blood with a pO


2


greater than 760 mmHg. Venous blood, on the other hand, typically has a pO


2


level less than 90 mmHg. In the average adult, for example, normal venous blood oxygen levels range generally from 40 mmHg to 70 mmHg.




Blood oxygen levels also may be described in terms of hemoglobin saturation levels. For normal arterial blood, hemoglobin saturation is about 97% and varies only as pO


2


levels increase. For normal venous blood, hemoglobin saturation is about 75%. Indeed, hemoglobin is normally the primary oxygen carrying component in blood. However, oxygen transfer takes place from the hemoglobin, through the blood plasma, and into the body's tissues. Therefore, the plasma is capable of carrying a substantial quantity of oxygen, although it does not normally do so. Thus, techniques for increasing the oxygen levels in blood primarily enhance the oxygen levels of the plasma, not the hemoglobin.




The techniques for increasing the oxygen level in blood are not unknown. For example, naval and recreational divers are familiar with hyperbaric chamber treatments used to combat the bends, although hyperbaric medicine is relatively uncommon for most people. Since hemoglobin is relatively saturated with oxygen, hyperbaric chamber treatments attempt to oxygenate the plasma. Such hyperoxygenation is believed to invigorate the body's white blood cells, which are the cells that fight infection. Hyperbaric oxygen treatments may also be provided to patients suffering from radiation injuries. Radiation injuries usually occur in connection with treatments for cancer, where the radiation is used to kill the tumor. Unfortunately, at present, radiation treatments also injure surrounding healthy tissue as well. The body keeps itself healthy by maintaining a constant flow of oxygen between cells, but radiation treatments can interrupt this flow of oxygen. Accordingly, hyperoxygenation can stimulate the growth of new cells, thus allowing the body to heal itself.




Radiation treatments are not the only type of medical therapy that can deprive cells from oxygen. In patients who suffer from acute myocardial infarction, for example, if the myocardium is deprived of adequate levels of oxygenated blood for a prolonged period of time, irreversible damage to the heart can result. Where the infarction is manifested in a heart attack, the coronary arteries fail to provide adequate blood flow to the heart muscle. The treatment for acute myocardial infarction or myocardial ischemia often involves performing angioplasty or stenting of vessels to compress, ablate, or otherwise treat the occlusions within the vessel walls. In an angioplasty procedure, for example, a balloon is placed into the vessel and inflated for a short period of time to increase the size of the interior of the vessel. When the balloon is deflated, the interior of the vessel will, hopefully, retain most or all of this increase in size to allow increased blood flow.




However, even with the successful treatment of occluded vessels, a risk of tissue injury may still exist. During percutaneous transluminal coronary angioplasty (PTCA), the balloon inflation time is limited by the patient's tolerance to ischemia caused by the temporary blockage of blood flow through the vessel during balloon inflation. Ischemia is a condition in which the need for oxygen exceeds the supply of oxygen, and the condition may lead to cellular damage or necrosis. Reperfusion injury may also result, for example, due to slow coronary reflow or no reflow following angioplasty. Furthermore, for some patients, angioplasty procedures are not an attractive option for the treatment of vessel blockages. Such patients are typically at increased risk of ischemia for reasons such as poor left ventricular function, lesion type and location, or the amount of myocardium at risk. Treatment options for such patients typically include more invasive procedures, such as coronary bypass surgery.




To reduce the risk of tissue injury that may be associated with treatments of acute myocardial infarction and myocardial ischemia, it is usually desirable to deliver oxygenated blood or oxygen-enriched fluids to the tissues at risk. Tissue injury is minimized or prevented by the diffusion of the dissolved oxygen from the blood to the tissue. Thus, in some cases, the treatment of acute myocardial infarction and myocardial ischemia includes perfusion of oxygenated blood or oxygen-enriched fluids. The term “perfusion” is derived from the French verb “perfuse” meaning “to pour over or through.” In this context, however, perfusion refers to various techniques in which at least a portion of the patient's blood is diverted into an extracorporeal circulation circuit, i.e., a circuit which provides blood circulation outside of the patient's body. Typically, the extracorporeal circuit includes an artificial organ that replaces the function of an internal organ prior to delivering the blood back to the patient. Presently, there are many artificial organs that can be placed in an extracorporeal circuit to substitute for a patient's organs. The list of artificial organs includes artificial hearts (blood pumps), artificial lungs (oxygenators), artificial kidneys (hemodialysis), and artificial livers.




During PTCA, for example, the tolerable balloon inflation time may be increased by the concurrent introduction of oxygenated blood into the patient's coronary artery. Increased blood oxygen levels also may cause the hypercontractility in the normally perfused left ventricular cardiac tissue to increase blood flow further through the treated coronary vessels. The infusion of oxygenated blood or oxygen-enriched fluids also may be continued following the completion of PTCA or other procedures, such as surgery, to accelerate the reversal of ischemia and to facilitate recovery of myocardial function.




Conventional methods for the delivery of oxygenated blood or oxygen-enriched fluids to tissues involve the use of blood oxygenators. Such procedures generally involve withdrawing blood from a patient, circulating the blood through an oxygenator to increase blood oxygen concentration, and then delivering the blood back to the patient. There are drawbacks, however, to the use of conventional oxygenators in an extracorporeal circuit. Such systems typically are costly, complex, and difficult to operate. Often, a qualified perfusionist is required to prepare and monitor the system. A perfusionist is a skilled health professional specifically trained and educated to operate as a member of a surgical team responsible for the selection, setup, and operation of an extracorporeal circulation circuit. The perfusionist is responsible for operating the machine during surgery, monitoring the altered circulatory process closely, taking appropriate corrective action when abnormal situations arise, and keeping both the surgeon and anesthesiologist fully informed. In addition to the operation of the extracorporeal circuit during surgery, perfusionists often function in supportive roles for other medical specialties to assist in the conservation of blood and blood products during surgery and to provide long-term support for patient's circulation outside of the operating room environment. Because there are currently no techniques available to operate and monitor an extracorporeal circuit automatically, the presence of a qualified perfusionist, and the cost associated therewith, is typically required.




Conventional extracorporeal circuits also exhibit other drawbacks. For example, extracorporeal circuits typically have a relatively large priming volume. The priming volume is typically the volume of blood contained within the extracorporeal circuit, i.e., the total volume of blood that is outside of the patient's body at any given time. For example, it is not uncommon for the extracorporeal circuit to hold one to two liters of blood for a typical adult patient. Such large priming volumes are undesirable for many reasons. For example, in some cases a blood transfusion may be necessary to compensate for the blood temporarily lost to the extracorporeal circuit because of its large priming volume. Also, heaters often must be used to maintain the temperature of the blood at an acceptable level as it travels through the extracorporeal circuit. Further, conventional extracorporeal circuits are relatively difficult to turn on and off. For instance, if the extracorporeal circuit is turned off, large stagnant pools of blood in the circuit might coagulate.




In addition to the drawbacks mentioned above, in extracorporeal circuits that include conventional blood oxygenators, there is a relatively high risk of inflammatory cell reaction and blood coagulation due to the relatively slow blood flow rates and large blood contact surface area of the oxygenators. For example, a blood contact surface area of about one to two square meters and velocity flows of about 3 centimeters/second are not uncommon with conventional oxygenator systems. Thus, relatively aggressive anticoagulation therapy, such as heparinization, is usually required as an adjunct to using the oxygenator.




Finally, perhaps one of the greatest disadvantages to using conventional blood oxygenation systems relates to the maximum partial pressure of oxygen (pO


2


) that can be imparted to the blood. Conventional blood oxygenation systems can prepare oxygen-enriched enriched blood having a partial pressure of oxygen of about 500 mmHg. Thus, blood having pO


2


levels near or above 760 mmHg, i.e., hyperbaric blood, cannot be achieved with conventional oxygenators.




It is desirable to deliver gas-enriched fluid to a patient in a manner which prevents or minimizes bubble nucleation and formation upon infusion into the patient. The maximum concentration of gas achievable in a liquid is ordinarily governed by Henry's Law. At ambient temperature, the relatively low solubility of many gases, such as oxygen or nitrogen, within a liquid, such as water, produces a low concentration of the gas in the liquid. However, such low concentrations are typically not suitable for treating patients as discussed above. Rather, it is advantageous to use a gas concentration within a liquid that greatly exceeds its solubility at ambient temperature. Compression of a gas and liquid mixture at a high pressure can be used to achieve a high dissolved gas concentration according to Henry's Law, but disturbance of a gas-saturated or a gas-supersaturated liquid by attempts to inject it into an environment at ambient pressure from a high pressure reservoir ordinarily results in cavitation inception at or near the exit port. The rapid evolution of bubbles produced at the exit port vents much of the gas from the liquid, so that a high degree of gas-supersaturation no longer exists in the liquid at ambient pressure outside the high-pressure vessel. In addition, the presence of bubbles in the effluent generates turbulence and impedes the flow of the effluent beyond the exit port. Furthermore, the coalescence of gas bubbles in blood vessels may tend to occlude the vessels and result in a gaseous local embolism that causes a decrease in local circulation, arterial hypoxemia, and systemic hypoxia.




In gas-enriched fluid therapies, such as oxygen therapies involving the use of hyperoxic or hyperbaric blood, delivery techniques are utilized to prevent or minimize the formation of cavitation nuclei so that clinically significant bubbles do not form within a patient's blood vessels. However, it should be understood that any bubbles that are produced tend to be very small in size, so that a perfusionist would typically have difficulty detecting bubble formation without the assistance of a bubble detection device. Unfortunately, known bubble detectors are ineffective for detecting bubbles in an extracorporeal circuit for the preparation and delivery of hyperoxic or hyperbaric blood. This problem results from the fact that the size and velocity of some bubbles are beyond the resolution of known bubble detectors. Therefore, micro bubbles (bubbles with diameters of about 50 micrometers to about 1000 micrometers) and some macro bubbles (bubbles with diameters greater than 1000 micrometers) may escape detection.











BRIEF DESCRIPTION OF THE DRAWINGS




The foregoing and other advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings in which:





FIG. 1

illustrates a perspective view of an exemplary system for producing gas-enriched fluid;





FIG. 2

illustrates a block diagram of the system of

FIG. 1

;





FIG. 3

illustrates a block diagram of the host/user interface used in the system of

FIG. 1

;





FIG. 4

illustrates an exemplary display;





FIG. 5

illustrates a block diagram of a blood pump system used in the system of

FIG. 1

;





FIG. 6

illustrates an interlock system used in the system of

FIG. 1

;





FIG. 7

illustrates a top view of an oxygenation device used in the system of

FIG. 1

;





FIG. 8

illustrates a cross-sectional view taken along line


8





8


in

FIG. 7

;





FIG. 9

illustrates a bottom view of the oxygenation device used in the system of

FIG. 1

;





FIG. 10

illustrates a detailed view of a check valve illustrated in

FIG. 8

;





FIG. 11

illustrates a detailed view of a piston assembly illustrated in

FIG. 8

;





FIG. 12

illustrates a cross-sectional view taken along line


12





12


of

FIG. 8

;





FIG. 13

illustrates a detailed view of a valve assembly illustrated in

FIG. 8

;





FIG. 14

illustrates a cross-sectional view of the valve assembly taken along line


14





14


in

FIG. 13

;





FIG. 15

illustrates a detailed view of a capillary tube illustrated in

FIG. 8

;





FIG. 16

illustrates a detailed view of a vent valve illustrated in

FIG. 8

;





FIG. 17

illustrates an exploded view of the cartridge and cartridge enclosure;





FIG. 18

illustrates a front view of the cartridge receptacle of the cartridge enclosure illustrated in

FIG. 1

;





FIG. 19

illustrates a cross-sectional view of the cartridge enclosure taken along line


19





19


in

FIG. 18

;





FIG. 20

illustrates the front view of a door latch on the door of the cartridge enclosure;





FIG. 21

illustrates a cross-sectional view of the door latch taken along line


21





21


in

FIG. 20

;





FIG. 22

illustrates another cross-sectional view of the door latch;





FIG. 23

illustrates a detailed view of the door latch of

FIG. 19

;





FIG. 24

illustrates a cross-sectional view of the door latch including a blocking mechanism;





FIG. 25

illustrates a cross-sectional view of the locking mechanism of

FIG. 24

as the latch is being closed;





FIG. 26

illustrates a cross-sectional view of the locking mechanism after the latch has been closed;





FIG. 27

illustrates a bottom view of the cartridge enclosure;





FIG. 28

illustrates a cross-sectional view taken along line


28





28


in

FIG. 27

of a valve actuation device in an extended position;





FIG. 29

illustrates a cross-sectional view taken along line


28





28


in

FIG. 27

of a valve actuation device in a retracted position;





FIG. 30

illustrates a top-view of the cartridge enclosure;





FIG. 31

illustrates a cross-sectional view taken along line


31





31


of

FIG. 30

of a valve actuation device in its extended position;





FIG. 32

illustrates a cross-sectional view taken along line


31





31


of

FIG. 30

of a valve actuation device in its retracted position;





FIG. 33

illustrates a cross-sectional view of the cartridge enclosure taken along line


33





33


in

FIG. 18

;





FIG. 34

illustrates a detailed view of an ultrasonic sensor illustrated in

FIG. 33

;





FIG. 35

illustrates a detailed view of an ultrasonic sensor illustrated in

FIG. 33

;





FIG. 36

illustrates a top view of the cartridge enclosure including gas connections;





FIG. 37

illustrates a cross-sectional view taken along line


37





37


in

FIG. 36

;





FIG. 38

illustrates a detailed view of the cross-sectional view of

FIG. 37

of a gas connection in an unseated position;





FIG. 39

illustrates a detailed view of the cross-sectional view of

FIG. 37

of a gas connection in a seated position;





FIG. 40

illustrates a partial cross-sectional view of a drive mechanism;





FIGS. 41A and B

illustrate an exploded view of the drive mechanism illustrated in

FIG. 40

;





FIG. 42

illustrates a cross-sectional view taken along line


42





42


in

FIG. 40

;





FIG. 43

illustrates a detailed view of the load cell illustrated in

FIG. 42

;





FIG. 44

illustrates an exploded view of a sensor assembly of the drive mechanism;





FIG. 45

illustrates a top partial cross-sectional view of the drive assembly;





FIG. 46

illustrates a cross-sectional view taken along line


46





46


of

FIG. 45

;





FIG. 47

illustrates a detailed view of a portion of the sensor assembly illustrated in

FIG. 46

;





FIG. 48

illustrates an exemplary sensor for use in the sensor assembly illustrated in

FIG. 44

;





FIG. 49

illustrates a state diagram depicting the basic operation of the system illustrated in

FIG. 1

;





FIG. 50

illustrates a block diagram of a system controller;





FIG. 51

illustrates a block diagram of a bubble detector;





FIG. 52

illustrates an exemplary signal transmitted by the bubble detector;





FIG. 53

illustrates an exemplary signal received by the bubble detector;





FIG. 54

illustrates a bubble sensor coupled to the return tube;





FIG. 55

illustrates a cross-sectional view of the return tube of

FIG. 54

;





FIG. 56

illustrates a schematic diagram of a system used to evaluate bubble detectors, such as the bubble detector of the present system;





FIG. 57

illustrates an elevated side view of an exemplary capillary tube;





FIG. 58

illustrates a side view of the capillary tube of

FIG. 57

positioned within a connecting device incident to a material flow;





FIG. 59

illustrates a schematic diagram of an alternative system used to evaluate bubble detectors, where the system includes a pulse dampener;





FIG. 60

illustrates a detailed view of an exemplary pulse dampener, and





FIG. 61

illustrates the output of a digital signal processor indicating the diameters of bubbles detected by the bubble detector.











DESCRIPTION OF SPECIFIC EMBODIMENTS




One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.




System Overview




Turning now to the drawings, and referring initially to

FIG. 1

, a system for preparing and delivering gas-enriched fluid is illustrated and designated by a reference numeral


10


. Although the system


10


may be used to prepare a number of different types of gas-enriched fluids, in this particular example, the system


10


prepares oxygen-enriched enriched blood. As will be described in detail herein, the system


10


is adapted to withdraw blood from a patient, combine the blood with a oxygen-supersaturated physiologic fluid, and deliver the oxygen-enriched blood back to the patient.




Because the system


10


may be used during surgical procedures, it is typically sized to be placed within a normal operating room environment. Although the system


10


may be configured as a stationary device or a fixture within an operating room, it is often desirable for various surgical devices to be mobile. Accordingly, in this example, the system


10


is illustrated as being coupled to a rolling base


12


via a pedestal


14


. Although some of the electrical and/or mechanical components of the system


10


may be housed in the base


12


or the pedestal


14


, these components will more typically be placed within a housing


16


. To facilitate positioning of the system


10


, a handle


18


may be coupled to the housing


16


for directing movement of the system


10


, and a pedal


20


may be coupled to the base


12


for raising and lowering the housing


16


on the pedestal


14


(via a rack and pinion mechanism which is not shown, for instance).




The housing


16


may include a cover, such as a hinged door


22


, for protecting certain components of the system


10


that are positioned in locations external to the housing


16


. Components that are typically located on the exterior of the housing


16


may include a blood pump


24


, a cartridge enclosure


26


, as well as various control devices


28


. Additional external items may include a user interface panel


30


and a display


32


.




Referring now to

FIG. 2

, a block diagram representing various components of the system


10


is illustrated. An appropriate draw tube


34


, such as an introducer sheath, is inserted into an appropriate blood vessel


36


of a patient


38


. Blood is drawn from the patient


38


through the draw tube


34


using the blood pump system


24


. Specifically, the blood pump system


24


includes a pump


40


, such as a peristaltic pump. As the peristaltic pump


40


mechanically produces waves of contraction along the flexible tube


34


, fluid within the tube


34


is pumped in the direction of the arrow


42


. As will be discussed in detail below, the blood pump system


24


includes a flow meter


46


that receives feedback from a flow probe


48


. The flow probe


48


is coupled to the patient's return tube


50


. With this feedback, the blood pump system


24


can operate as an automatic extracorporeal circuit that can adjust the r.p.m. of the peristaltic pump


40


to maintain the desired blood flow.




The draw tube


34


and/or the return tube


50


may be sub-selective catheters. The construction of the return tube


50


may be of particular importance in light of the fact that the gas-enriched bodily fluid may be gas-saturated or gas-supersaturated over at least a portion of the length of the return tube


50


. Therefore, the return tube


50


, in particular, is typically designed to reduce or eliminate the creation of cavitation nuclei which may cause a portion of the gas to come out of solution. For example, the length-to-internal diameter ratio of the catheter may be selected to create a relatively low pressure drop from the oxygenation device


54


to the patient


38


. Typically, the catheter is sized to fit within a 6 french guide catheter. Materials such as polyethylene or PEBAX (polyetheramide), for example, may be used in the construction of the catheter. Also, the lumen of the catheter should be relatively free of transitions that may cause the creation of cavitation nuclei. For example, a smooth lumen having no fused polymer transitions typically works well.




The blood is pumped through the draw tube


34


in the direction of the arrow


52


into an oxygenation device


54


. Although various different types of oxygenation devices may be suitable for oxygenating the patient's blood prior to its return, the oxygenation device


54


in the system


10


advantageously prepares an oxygen-supersaturated physiologic fluid and combines it with the blood to enrich the blood with oxygen. Also, the oxygenation device


54


is advantageously sterile, removable, and disposable, so that after the procedure on the patient


38


has been completed, the oxygenation device


54


may be removed and replaced with another oxygenation device


54


for the next patient.




Advantages of the oxygenation device


54


will be described in great detail below. However, for the purposes of the discussion of

FIG. 2

, it is sufficient at this point to understand that the physiologic fluid, such as saline, is delivered from a suitable supply


56


, such as an IV bag, to a first chamber


58


of the oxygenation device


54


under the control of a system controller


55


. A suitable gas, such as oxygen, is delivered from a supply


60


, such as a tank, to a second chamber


62


of the oxygenation device


54


. Generally speaking, the physiologic fluid from the first chamber


58


is pumped into the second chamber


62


and atomized to create a oxygen-supersaturated physiologic solution. This oxygen-supersaturated physiologic solution is then delivered into a third chamber


64


of the oxygenation device


54


along with the blood from the patient


38


. As the patient's blood mixes with the oxygen-supersaturated physiologic solution, oxygen-enriched blood is created. This oxygen-enriched blood is taken from the third chamber


64


of the oxygenation device


54


by the return tube


50


.




A host/user interface


66


of the system


10


monitors both the pressure on the draw tube


34


via a draw pressure sensor


68


and the pressure on the return tube


50


via a return pressure sensor


70


. As illustrated in

FIG. 6

, the ends of the draw tube


34


and the return tube


50


that couple to the oxygenation device


54


are embodied in a Y-connector


71


in this example. The Y-connector


71


includes the draw pressure sensor


68


and the return pressure sensor


70


, which are operatively coupled to the host/user interface


66


via an electrical connector


73


. The host/user interface


66


may deliver these pressure readings to the display


32


so that a user can monitor the pressures and adjust them if desired. The host/user interface


66


also receives a signal from a level sensor


72


that monitors the level of fluid within the mixing chamber


64


of the oxygenation device


54


to ensure that the oxygen-supersaturated physiological solution is mixing with the patient's blood with little or no bubble formation.




The system


10


further advantageously includes a suitable bubble detector


74


. The bubble detector


74


includes a suitable bubble sensor


76


positioned at the return tube


50


to detect bubbles as they pass through the return tube


50


to the patient


38


. Again, as discussed in greater detail below, the bubble detector


74


receives the signals from the bubble sensor


76


and processes information regarding the nature of any bubbles that may be traveling in the oxygen-enriched blood going back to the patient


38


. In this embodiment, the bubble detector


74


provides this information to the host/user interface


66


so that information regarding bubbles in the effluent may be provided to the user via the display


32


. The bubble detector


74


may also control or shut down the system


10


in certain circumstances as discussed in detail below.




The system


10


also includes an interlock system


44


. The interlock system


44


communicates with many of the components of the system


10


for various reasons. The interlock system


44


monitors the various components to ensure that the system


10


is operating within certain prescribed bounds. For example, the interlock system


44


receives information regarding draw and return pressures from the pressure sensors


68


and


70


, information regarding fluid level in the mixing chamber


64


from the level sensor


72


, and information regarding the number and/or size of bubbles from the bubble detector


74


, as well as other information regarding the operating states of the various components. Based on this information, the interlock system


44


can shut down the system


10


should it begin to operate outside of the prescribed bounds. For example, the interlock system


44


can engage clamps


78


and


80


on the draw tube


34


and the return tube


50


, respectively, as well as disable the blood pump system


24


and the system controller


55


that controls the oxygenation device


54


. While the interlock system


44


typically operates in this automatic fashion, a safety switch


82


may be provided so that a user can initiate a shutdown of the system


10


in the same fashion even if the system


10


is operating within its prescribed bounds.




The system


10


has a low priming volume relative to conventional extracorporeal circuits, typically in the range of 25 to 100 milliliters. Thus, a heater typically is not used with the system


10


. However, if it is desirable to control the temperature of the incoming blood in the draw tube


34


or the outgoing gas-enriched blood in the return tube


50


, an appropriate device, such as a heat exchanger, may be operatively coupled to one or both of the tubes


34


and


50


. Indeed, not only may the heat exchanger (not shown) be used to warm the fluid as it travels through the system


10


, it may also be used to cool the fluid. It may be desirable to cool the fluid because moderate hypothermia, around 30° C. to 34° C. has been shown to slow ischemic injury in myocardial infarction, for example.




Host/User Interface




The various details of the system


10


described above with reference to

FIGS. 1 and 2

will be described with reference to the remaining Figs. Turning now to

FIG. 3

, an exemplary embodiment of the host/user interface


66


is illustrated. The host/user interface


66


includes a user interface


84


and a host interface


85


. The user interface


84


may include a user input and display device, such as a touch screen display


86


. As illustrated in

FIG. 4

, the touch screen display


86


may include “buttons”


87


that initiate certain operations when a user touches them. The touch screen display


86


may also include information such as alarms/messages


88


, status indicators


89


, blood flow information


90


, and bubble count


91


.




The user inputs are handled by a touch screen driver


92


, and the displayed information is handled by a display driver


93


. The touch screen driver


92


transmits user inputs to an interface, such as an RS-232 interface


94


. The RS-232 interface


94


may communicate these user inputs to other portions of the system


10


, such as the system controller


55


, the interlock system


44


, the blood pump system


24


, and the bubble detector


74


. The display driver


93


communicates with a display controller


95


, which is also coupled to the RS-232 interface


94


via a bus


96


. The display controller


95


receives updated information from the various other portions of the system


10


, and it uses this information to update the display


86


.




The host interface


85


may also include various other capabilities. For example, the host interface


85


may include a sound card


97


to drive speakers


98


on the user interface


84


. In addition, a network adapter


99


may allow the host interface


85


to communicate with an external network, such as a LAN in the hospital or a remote network for providing updates for the system


10


, e.g., the Internet. Finally, the host interface


85


may include an analog and/or digital I/O device


101


, which in this example transmits and receives certain signals such as an enable signal, a “request to stop” signal, a draw pressure signal, and a return pressure signal.




Blood Pump System and Interlock System




Many of the components described below, while particularly useful in the exemplary system


10


, may be quite useful in other types of systems as well. For example, the blood pump system


24


described in detail with reference to

FIG. 5

may be used not only in the context of the system


10


, but also in other types of perfusion systems, such as conventional heart-lung machines and other types of other extracorporeal circuits. As previously discussed, the blood pump system


24


utilizes a suitable pump


40


, such as a peristaltic pump, to draw blood from the patient


38


through a draw tube


34


. The blood pump system


24


further includes a flow meter


46


, such as a transonic flow meter, which communicates with a flow transducer


48


via lines


100


and


102


. The feedback from the transducer


48


enables the blood pump system


24


to maintain the desired flow rate. The desired flow rate may be entered by a user, such as perfusionist or a nurse, via the control panel


30


. In this example, the control panel


30


includes an indication of the current blood flow rate in milliliters per minute, as well as an “up” button


104


and a “down” button


106


that permit a user to adjust the blood flow rate upwardly and downwardly, respectively. The control panel


30


further includes a “prime” button


108


, a “start” button


110


, and a “stop” button


112


. In addition, the control panel


30


may be augmented by a foot switch


114


, which includes a stop pedal


116


, which performs the same function as the stop button


112


, and a prime start pedal


118


, which performs the same function as the prime button


108


and the start button


110


.




Because the blood pump system


24


utilizes feedback from the flow transducer


48


to maintain and adjust the r.p.m. of the pump


40


in a manner which provides a consistent flow rate, the blood pump system


24


requires no user interaction once the system has been primed and the flow rate has been set. Therefore, unlike blood pumps used in other extracorporeal circuits, the blood pump system


24


may be operated by a semi-skilled technician or nurse, rather than a highly skilled perfusionist.




To provide an extra measure of confidence with such semi-skilled operation, the blood pump system


24


takes advantage of certain features provided by the interlock system


44


. For example, referring to the interlock system


44


illustrated in

FIG. 6

as well, the interlock system


44


may include or have access to a personality module


120


. The personality module


120


may include a memory


122


, such as a read only memory for example. The memory


122


of the personality module


120


may include various information, such as flow rates and ranges, as well as other information to be discussed below. Therefore, for a particular patient or for a particular type of patient, the desired flow rate and/or the desired flow rate range may be programmed into the memory


122


. For example, in acute myocardial infarction applications, the flow rate may be 75 milliliters per minute, or for stroke applications the flow rate may be 300 milliliters per minute. In this exemplary embodiment, the personality module


120


may be located in the Y-connector


71


. Because the information programmed into the personality module


120


may be related to a particular patient or a particular type of patient, and because a new Y-connector is typically used with each patient, the location of the personality module


120


in the Y-connector


71


provides an effective method of customizing the system


10


with each patient treated.




The interlock system


44


reads this flow information from the memory


122


and compares it to the flow rate delivered by the flow meter


46


on line


124


. As long as the flow rate from the flow meter


46


is maintained at the desired flow rate or within the desired flow range programmed into the memory


122


, the interlock system


44


will continue to supply an enable signal on line


126


to the blood pump system


24


. However, should the flow rate fall outside of the desired range, due to operator intervention, failure of the flow transducer


48


, etc., the interlock system


44


will switch the signal on the line


126


to disable the blood pump system


24


. The interlock system


44


will further actuate the clamps


78


and


80


in order to shut down the system


10


in a manner safe for the patient


38


.




The interlock system


44


includes an analog conditioning circuit


130


that receives and conditions the analog flow rate signal from the flow meter


46


on the line


124


. This conditioned signal is compared with the information from the memory


122


using comparators and threshold settings


132


. The results of this comparison are delivered to a logic block


134


, which may be, for example, a field programmable gate array (FPGA) or a complex programmable logic device (CPLD). The logic block


134


generates the enable or disable signal on the line


126


.




The conditioning circuit


130


also receives the analog pressure signals from the draw pressure transducer


68


and the return pressure transducer


70


. These pressures may be monitored to ensure that neither the draw tube


34


nor the return tube


50


are kinked or otherwise unable to deliver fluid at a minimum desired pressure or higher. The logic block


134


compares these pressures to the minimum pressure setting, e.g., −300 mm Hg, and delivers a warning signal if either pressure drops below the minimum pressure setting. In addition, the draw pressure is monitored to ensure that it remains higher than a minimal draw pressure threshold, e.g. −300 mm Hg, to ensure that bubbles are not pulled out of solution by the blood pump


40


. Still further, the return pressure is monitored to ensure that it does not exceed a maximum return pressure, e.g. 2000 mm Hg.




The manner in which the interlock system


44


interfaces with various other portions of the system


10


will be discussed below where appropriate. However, it can be seen that the blood pump system


24


and the interlock system


44


provide a technique by which blood may be removed from a patient at a desired and maintainable flow rate and that any deviation from the desired flow rate will cause the system to shut down in a manner which is safe for the patient


38


. Accordingly, the use of a perfusionist may be obviated in most circumstances.




Oxygenation Device




Although the blood pump system


24


may be used in a variety of different systems, for the primary purpose of this discussion it is incorporated within the system


10


. As described in reference to

FIG. 2

above, one of its main purposes is to deliver blood to the oxygenation device


54


. Accordingly, before discussing the blood pump system


24


or the other components further, an understanding of the manner in which the oxygenation device


54


functions is appropriate.




Referring first to

FIGS. 7

,


8


, and


9


, an exemplary embodiment of an oxygenation device


54


is illustrated. As mentioned previously, the oxygenation device


54


includes three chambers: a fluid supply chamber


58


, an atomization chamber


62


, and a mixing chamber


64


. Generally speaking, physiologic fluid, such as saline, is drawn into the fluid supply chamber


58


. The physiologic fluid is transferred under pressure from the fluid supply chamber


58


to the atomization chamber


62


. In the atomization chamber


62


, the physiologic fluid is enriched with a gas, such as oxygen, to form a gas-enriched physiologic fluid. For example, the physiologic fluid may be supersaturated with the gas. The gas-enriched physiologic fluid is transferred to the mixing chamber


64


to be combined with a bodily fluid, such as blood. The mixing of the gas-enriched physiologic fluid with the bodily fluid forms a gas-enriched bodily fluid. In one example, blood from a patient is mixed with an oxygen-supersaturated saline solution and transmitted back to the patient.




Beginning with a detailed discussion of the fluid supply chamber


58


, an appropriate delivery device, such as a tube


140


, is coupled to a supply of physiologic fluid. In this example, the tube


140


may include a drip chamber


141


and is coupled at one end to an IV bag


56


. The other end of the tube


140


is coupled to a nozzle


142


. The nozzle


142


forms a portion of a fluid passageway


144


that leads to the fluid supply chamber


58


. A check valve


146


is disposed in the fluid passageway


144


so that fluid may enter the fluid chamber


58


through the fluid passageway


144


, but fluid cannot exit through the fluid passageway


144


.




As illustrated by the detailed view of

FIG. 10

, check valve


146


has an O-ring seal


148


that is disposed between a lip in the fluid passageway


144


and the nozzle


142


. A spring


150


biases a ball


152


into contact with the O-ring seal


148


. When fluid moving in the direction of the arrow


154


overcomes the force of the spring


150


and the pressure within the fluid supply chamber


58


, the ball


152


is pushed against the spring


150


so that fluid may flow into the fluid supply chamber


58


. However, fluid cannot flow in the opposite direction because the ball


152


efficiently seals against the O-ring seal


148


.




A piston assembly


160


is disposed at the opposite end of the fluid supply chamber


58


. The piston assembly


160


includes a sleeve


162


that is fixedly disposed within the fluid supply chamber


58


. As illustrated in greater detail in

FIG. 11

, a plunger


164


is slidably disposed within the sleeve


162


. A cap


166


is disposed at one end of the plunger


164


. The cap includes a flange


168


that has an outer diameter greater than the inner diameter of the sleeve


162


to limit downward movement of the piston assembly


160


. Although the sleeve


162


, the plunger


164


, and the cap


166


are advantageously made of a relatively rigid material, such as plastic, a relatively resilient end piece


170


is disposed on the cap


166


. The end piece


170


advantageously includes sealing members


172


that seal against the interior walls of the fluid supply chamber


58


.




As illustrated by the phantom lines in

FIG. 11

, the piston assembly


160


is moveable between a first position (shown by the solid lines) and a second position (shown by the phantom lines). To facilitate this movement, a device to be described below is coupled to the free end


174


of the piston assembly


160


. Although such coupling may occur in various suitable manners, in this example a key


176


is provided at the free end


174


of the piston assembly


160


. The key


176


includes a narrow portion


178


and a relatively wider portion


180


so that it somewhat resembles a doorknob, thus allowing a device to latch onto the piston assembly


160


and move it between the first and second positions.




As will be appreciated from a thorough study of this entire discussion, one of the primary advantages of the particular oxygenation device


54


disclosed herein involves its sterility and disposability. The sterility of the piston assembly


160


may be facilitated by providing a sterility sheath


182


disposed between the cap


166


and the sleeve


162


. In this embodiment, the sterility sheath


182


includes an extendable tube


184


that is coupled to the cap


166


by a clamp


186


and coupled to the outer portion of the sleeve


162


by a clamp


188


. The expandable tube


184


may take various forms, such as a plastic tube that folds in an accordion-like manner when the piston assembly


160


is in its retracted position (as shown by the solid lines). However, the expandable tube


184


may take various other forms, such as a flexible member that stretches between the retracted position and the extended position of the piston assembly


160


. The clamps


186


and


188


may also take various suitable forms, such as rubber O-rings in this example.




Referring additionally to

FIG. 12

, the fluid supply chamber


58


further includes a second fluid passageway


190


. As illustrated by way of a specific example in the present embodiment, the fluid passageway


190


is coupled to a fluid passageway


194


by a tube


196


. The passageway


194


is an inlet to a valve assembly


200


that controls the manner in which fluid from the fluid supply chamber


58


is delivered into the atomization chamber


62


.




In operation, the piston assembly


160


within the fluid supply chamber


58


acts as a piston pump. As the piston assembly


160


retracts, fluid is drawn into the chamber


58


from the fluid supply


56


. No fluid can be drawn from passageway


190


because valve assembly


200


is closed and a check valve


192


is closed in this direction. As the piston assembly


160


extends, the fluid within the chamber


58


is pressurized, typically to about 670 psi, and expelled from the fluid supply chamber


58


through the fluid passageway


190


. The outlet of the fluid supply chamber


58


is coupled to an inlet of the atomization chamber


62


via an appropriate fluid passageway.




Detailed views of the valve assembly


200


are illustrated in

FIGS. 13 and 14

. The valve assembly


200


includes three valves: a fill valve


202


, a flush valve


204


, and a flow valve


206


. While any suitable valve arrangement and type of valve may be used, in this embodiment the valves


202


,


204


, and


206


are needle valves that are normally biased in the closed position as shown. When the pressure within the atomization chamber


62


rises above a certain level, such as about 100 psi, the valves


202


,


204


, and


206


will move from the closed position to the opened position, assuming that they are allowed to do so. In this embodiment, as will be discussed in greater detail below, push pins and associated actuation mechanisms (as illustrated by the phantom lines in

FIG. 13

) maintain the valves


202


,


204


, and


206


in the closed positions until one or more of the valves


202


,


204


, and


206


is to be opened.




Gas, such as oxygen, is delivered under pressure to the atomization chamber


62


via a passageway


210


. For example, the oxygen tank


60


may be coupled to the inlet of the passageway


210


to provide the desired oxygen supply. If all of the valves


202


,


204


, and


206


are closed, fluid flows from the inlet passageway


194


into a passageway


212


in which the fill valve


202


is located. Because the cross-sectional area of the passageway


212


is larger than the cross-sectional area of the fill valve


202


, the fluid flows around the closed fill valve


202


and into a passageway


214


that leads to an atomizer


216


.




The atomizer


216


includes a central passageway


218


in which a one-way valve


220


is disposed. In this embodiment, the one-way valve


220


is a check valve similar to that described with reference to FIG.


10


. Accordingly, when the fluid pressure overcomes the force of the spring in the one-way valve


220


and overcomes the pressure of the gas within the atomizer chamber


62


, the fluid travels through the passageway


218


and is expelled from a nozzle


222


at the end of the atomizer


216


.




The nozzle


222


forms fluid droplets into which the oxygen within the atomization chamber


62


diffuses as the droplets travel within the atomization chamber


62


. This oxygen-enriched fluid may be referred to herein as aqueous oxygen (AO). In this embodiment, the nozzle


222


forms a droplet cone defined by the angle α, which is typically about 20 degrees to about 40 degrees at normal operating pressures, e.g., about 600 psi, within the atomization chamber


62


. The nozzle


222


is a simplex-type, swirled pressurized atomizer nozzle including a fluid orifice of about 0.004 inches diameter to 0.005 inches diameter. It should be appreciated that the droplets infused with the oxygen fall into a pool at the bottom of the atomizer chamber


62


. Since the atomizer


216


will not atomize properly if the level of the pool rises above the level of the nozzle


222


, the level of the pool is controlled to ensure that the atomizer


216


continues to function properly.




The oxygen is dissolved within the atomized fluid to a much greater extent than fluid delivered to the atomizer chamber


62


in a non-atomized form. As previously stated, the atomizing chamber typically operates at a constant pressure of about 600 psi. Operating the atomizer chamber


62


at 600 psi, or any pressure above 200 psi, advantageously promotes finer droplet formation of the physiologic solution from the atomizer


216


and better saturation efficiency of the gas in the physiologic fluid than operation at a pressure below 200 psi. As will be explained shortly, the oxygen-supersaturated fluid formed within the atomizer chamber


62


is delivered to the mixing chamber


64


where it is combined with the blood from the patient


38


. Because it is desirable to control the extent to which the patient's blood is enriched with oxygen, and to operate the system


10


at a constant blood flow rate, it may be desirable to dilute the oxygen-supersaturated fluid within the atomizer chamber


62


to reduce its oxygen content. When such dilution is desired, the fill valve


202


is opened to provide a relatively low resistance path for the fluid as compared to the path through the atomizer


216


. Accordingly, instead of passing through the atomizer


216


, the fluid flows through a passageway


230


which extends upwardly into the atomizer chamber


62


via a tube


232


. The tube


232


is advantageously angled somewhat tangentially with respect to the cylindrical wall of the atomizer chamber


62


so that the fluid readily mixes with the oxygen-supersaturated fluid in the pool at the bottom of the atomizer chamber


62


.




The valve assembly


200


essentially performs two additional functions. First, with the fill valve


202


and the flow valve


206


closed, the flush valve


204


may be opened so that fluid flows from the inlet passageway


194


, through the passageways


212


and


214


, and into passageways


240


and


242


, the latter of which has a cross-sectional area larger than the cross-sectional area of the flow valve


206


. Thus, the fluid flows out of an outlet passageway


244


that is coupled to a capillary tube


246


. The capillary tube


246


terminates in a tip


248


that extends upwardly into the mixing chamber


64


. Since this fluid has not been gas-enriched, it essentially serves to flush the passageways


242


and


244


, and the capillary tube


246


to remove any contaminants and to ensure adequate fluid flow. Second, with the fill valve


202


and the flush valve


204


closed, the flow valve


206


may be opened when it is desired to deliver the gas-supersaturated fluid from the pool at the bottom of the atomizer chamber


62


into the mixing chamber


64


.




In this second circumstance, the gas-supersaturated fluid readily flows from the atomization chamber


62


through the capillary tube


246


and into the mixing chamber


64


due to the fact that pressure within the atomization chamber


62


is relatively high, e.g., approximately 600 psi, and pressure within the mixing chamber


64


is relatively low, e.g., about 30 psi. The end of the capillary tip


248


is advantageously positioned below a blood inlet


250


of the mixing chamber


64


. This spacial arrangement typically ensures that the blood flowing through the draw tube


34


and into the blood inlet


250


effectively mixes with the oxygen-supersaturated fluid flowing into the mixing chamber


64


through the capillary tip


248


. Finally, by the force of the blood pump system


24


, the oxygenated blood is pumped out of the mixing chamber


64


through an outlet


252


into the return tube


50


.




Typically, the capillary tube


246


and the capillary tip


248


are relatively long to ensure that proper resistance is maintained so that the oxygen within the oxygen-supersaturated fluid remains in solution as it travels from the atomization chamber


62


into the mixing chamber


64


. For example, the capillary tube


246


and the tip


248


may be in the range of 50 microns to 300 microns in length and in the range of 3 inches to 20 inches in internal diameter. To maintain the compact size of the oxygenation device


54


, therefore, the capillary tube


246


is wrapped about the exit nozzle


252


of the mixing chamber


64


, as illustrated in the detailed drawing of FIG.


15


. To protect the coiled capillary tube


246


from damage, a protective shield


254


is advantageously formed around the coiled capillary tube


246


to create a compartment


256


.




Both the atomization chamber


62


and the mixing chamber


64


include vent valves


258


and


260


, respectively. The vent valves


258


and


260


, as illustrated in the detail drawing of

FIG. 16

, are one-way valves that allow gas pressure to be vented out of the oxygenation device


54


and into the atmosphere. In this particular embodiment, the vent valves


258


and


260


include a plunger


262


that is biased in a closed position against an O-ring seal


264


by a spring


266


. The biasing force is light so that only one to two psi within the respective chambers


62


or


64


is sufficient to move the plunger


262


away from the seal


264


to vent the chamber. Therefore, as will be discussed in greater detail below, actuation devices that are part of the cartridge enclosure


26


and controlled by the system controller


55


normally maintain the valves


258


and


260


in the closed position.




Before beginning a discussion of the remainder of the system


10


, a few points regarding oxygenation of blood in general, and the use of the disclosed oxygenation device


54


in particular, should be noted. First, various methods of oxygenating blood are known or under development. Although an atomizing chamber provides a convenient mechanism for diffusing relatively large amounts of gas into a fluid in a relatively short period of time, it is not the only way of dissolving gas within a fluid. Indeed, other devices, such as membrane oxygenators, gas spargers, bubblers, and thin film oxygenation devices, may be used to perform this function as well. Second, although a piston pump similarly provides a compact and efficient method of pressurizing fluid prior to sending it to an oxygenator, such as the atomizer, other types of pumps or methods of pressurization may be used as well. Third, although a mixing chamber provides a compact environment in which the mixing of the gas-supersaturated fluid with blood may be appropriately monitored and controlled, gas-enriched fluid may be mixed with blood in other ways. For example, gas-supersaturated fluid may be mixed with blood within the mixing zone of a catheter or other suitable device. Therefore, although a piston pump, atomizer, and mixing chamber comprise the oxygenation device


54


utilized in the exemplary embodiment of the system


10


, due to certain perceived advantages, other devices can, generally speaking, perform these functions.




With these generalities in mind, the oxygenation device


54


disclosed herein offers several advantages that make it particularly attractive for use within a medical environment. First, the oxygenation device


54


is advantageously made from a clear plastic, such as polycarbonate which can be molded to provide a high strength, low cost device. Second, the oxygenation device


54


is relatively compact, with an exemplary specimen measuring approximately 12 cm in height, 10 cm in width, and 5.5 cm in depth. Thus, it can be utilized within a system


10


that fits easily within an operating room or special procedures lab, regardless of whether the system


10


is fixed or mobile. Third, the oxygenation device


54


combines the preparation of the oxygen-enriched fluid, along with the mixing of the oxygen-enriched fluid with the blood, into a unitary device utilizing only four connections: (1) fluid supply, (2) oxygen supply, (3) blood supply, and (4) blood return. The other connections are part of the oxygenation device


54


itself, and they require no additional connection from the user. Fourth, all of the valves used to operate the oxygenation device


54


are integrated within its unitary structure. Thus, the valves and their associated fluid passageways are protected against external contamination, and users are protected against any contamination that may arise from the use of the various fluids as well. As a result, the oxygenation device


54


is a relatively contamination-free cartridge that may be used during a surgical procedure on a patient, and then removed and replaced prior to performing a surgical procedure on the next patient.




Cartridge Enclosure




Prior to discussing the remainder of the electrical components and the manner in which they control the various mechanical components of the system


10


, the manner in which certain mechanical components interface with the oxygenation device


54


will now be discussed. As mentioned previously, the oxygenation device


54


is placed inside of the cartridge enclosure


26


.

FIG. 17

illustrates an exploded view of the cartridge enclosure


26


, and

FIG. 18

illustrates a front view of the cartridge enclosure


26


. In this embodiment, the cartridge enclosure


26


includes a cartridge receptacle


302


that is accessed by a hinged door


304


. When the oxygenation device


54


is placed within the cartridge receptacle


302


, the door


304


is closed and latched for various reasons. First, the cartridge receptacle


302


and the oxygenation device


54


are sized and shaped in a complementary fashion so that the various surfaces, vents, valves, etc. are positioned in a desired manner. When the door


304


is closed and latched, an inner surface


306


of the door


304


advantageously presses against a surface


308


of the oxygenation device


54


to ensure that the positioning of the oxygenation device


54


is accurate. Second, the door


304


is advantageously locked to prevent removal of the oxygenation device


54


during normal operation of the system


10


. Accordingly, the door


304


is provided with a latch


310


. Referring to

FIGS. 19-26

, the door latch


310


includes a handle portion


312


and a latching portion


314


.




To latch the door


304


, a user grasps the handle portion


312


to pivot the latch


310


about a pivot pin


316


generally in the direction of the arrow


318


. As the latch


310


pivots in the direction of the arrow


318


, the latching portion


314


hooks around a latch pin


320


. The latch pin


320


is coupled to a biasing mechanism


322


. The biasing mechanism


322


, in this embodiment, includes two pins


324


and


326


that extend through holes in a wall


328


. A respective spring


330


and


332


is disposed about each pin


324


and


326


to bias the latch pin


320


toward the wall


328


. As the latching portion


314


hooks around the latch pin


320


, the latch


310


may tend to overcome the bias of the springs


330


and


332


to move the latching mechanism


322


slightly in the direction of the arrow


334


. However, due to the bias of the latching mechanism


322


, it tends to hold the latch


310


, and thus the door


304


, tightly in place.




To keep the latch


310


in place, and thus lock the door


304


, a locking mechanism


340


is provided. In this embodiment, the locking mechanism includes


340


a slidable pin


342


that is disposed in a portion of the wall


328


. As the latch


310


moves in the direction of the arrow


318


, it eventually contacts the front end of the pin


342


, and thus moves it in the direction of the arrow


344


. The rear portion of the pin


342


is coupled to a piston


346


of a pull-type solenoid


348


. The piston


346


is biased outwardly by a spring


350


, so that the piston


346


is normally in an extended position.




The latch


310


is configured so that as it reaches its latched position, the spring


350


pushes the pin


342


in the direction of the arrow


352


so that the pin


342


extends over a portion


354


of the latch


310


. With the pin


342


in its locked position over the portion


354


of the latch


310


, the latching portion


314


cannot be removed from the latching mechanism


322


. Instead, the latch


310


remains locked until the piston


346


of the solenoid


348


is retracted to move the pin


342


out of the way of the latch


310


.




It should also be noted that the latch


310


includes a sensor


360


that provides an electrical signal indicative of whether the latch


310


is in its locked position. In this embodiment, the sensor


360


is a Hall effect sensor. The latch


310


includes a magnet


362


that is positioned to align with the sensor


360


when the latch


310


is in the locked position. When the magnet


362


is aligned with the sensor


360


, the electromagnetic signal is uninterrupted. However, until the magnet


362


reaches alignment, the electromagnetic signal from the sensor


360


is interrupted, thus indicating that the latch


310


is not yet in its locked position.




Valve Actuation




As mentioned previously, in the present embodiment, the size and shape of the oxygenation device


54


, the contour of the cartridge receptacle


302


, and the closing of the door


304


ensure that the oxygenation device


54


is positioned in a desired manner within the cartridge enclosure


26


. Correct positioning is of concern due to the placement of the valves and vents of the oxygenation device


54


and the manner in which they are controlled and actuated. As mentioned earlier, the valves and vents of the oxygenation device


54


are actuated using pins in this embodiment. The top of the oxygenation device includes vents


258


and


260


, and the bottom of the oxygenation device


54


includes three valves,


202


,


204


, and


206


. In this embodiment, these vents


258


and


260


and valves


202


,


204


and


206


are electromechanically actuated using solenoid-actuated pins.




A detailed view of these actuation devices is illustrated in

FIGS. 27-32

. Referring first to

FIG. 27

, a bottom view of the cartridge enclosure


26


is illustrated. The oxygenation device


54


is illustrated by phantom lines. It should be noted that the bottom portion of the cartridge enclosure


26


advantageously includes a slot


380


through which the blood return tube


50


of the oxygenation device


54


may pass. Once the oxygenation device


54


is in place within the cartridge enclosure


26


, the fill valve


202


, the flush valve


204


, and the flow valve


206


should be in alignment with respective actuation pins


382


,


384


, and


386


. Advantageously, each of the pins


382


,


384


, and


386


is tapered at the end to provide an increased tolerance for misalignment. Each of the actuation pins


382


,


384


, and


386


is moved between a closed position and an open position by a respective solenoid


388


,


390


, and


392


. Each of the solenoids


388


,


390


, and


392


is coupled to its respective actuation pin


382


,


384


, and


386


via a respective lever


394


,


396


, and


398


. Each of the respective levers


394


,


396


, and


398


pivots on a respective fulcrum or pivot pin


400


,


402


, and


404


.




The manner in which the actuators operate may be understood with reference to

FIGS. 28 and 29

. While these figures only illustrate the actuator for the flush valve


204


, it should be understood that the other actuators operate the fill valve


202


and the flow valve


206


in the same manner. As mentioned previously, the valves


202


,


204


, and


206


are normally held in a closed position. Accordingly, in this particular embodiment, the solenoids


388


,


390


, and


392


are pull-type solenoids. As illustrated in

FIG. 28

, a piston


406


of the pull-type solenoid


390


is urged into an extended position by a spring


408


that biases one end of the lever


396


generally in the direction of the arrow


410


. As a result, the spring


408


also biases the actuation pin


384


generally in the direction of the arrow


412


to maintain the flush valve


204


in its closed position.




To allow the flush valve


204


to open, the solenoid


390


is actuated as illustrated in FIG.


29


. The actuation of the pull-type solenoid


390


moves the piston


406


generally in the direction of the arrow


414


into a retracted position. The force of the solenoid


390


overcomes the bias of the spring


408


and moves the actuation pin


384


generally in the direction of the arrow


416


. With the actuation pin


384


in a retracted position, the flush valve


204


may open by moving in the direction of the arrow


416


.




The actuation of the vent valves


258


and


260


takes place in a similar fashion. Referring now to

FIG. 30

, a top view of the cartridge enclosure


26


is illustrated. The top portion of the cartridge enclosure


26


also includes a slot


420


through which the IV tube


140


may pass. Once the oxygenation device


54


is properly positioned within the cartridge enclosure


26


, the vent valves


258


and


260


align with actuation pins


422


and


424


, respectively. The pins


422


and


424


are also advantageously tapered at the ends to increase tolerance to misalignment. Each of the actuation pins


422


and


424


is actuated by a respective solenoid


426


and


428


. Each of the solenoids


426


and


428


is coupled to the respective actuation pin


422


and


424


by a respective lever


430


and


432


. Each of the levers


430


and


432


pivots about a fulcrum or pivot pin


434


and


436


, respectively.




As described with reference to

FIGS. 31 and 32

, the operation of the actuators for the valves


258


and


260


is similar to the operation of the actuators for the valves


202


,


204


, and


206


. Although

FIGS. 31 and 32

illustrate only the actuator for the vent valve


260


, it should be understood that the actuator for the vent valve


258


operates in a similar manner. Referring first to

FIG. 31

, the solenoid


428


in this embodiment is a pull-type solenoid. A spring


440


generally biases the lever arm


432


in the direction of the arrow


442


to move a piston


444


of the solenoid


428


into an extended position. Accordingly, by virtue of the action of the lever


432


about the pivot pin


436


, the spring


440


moves the actuation pin


424


into an extended position. In the extended position, the actuation pin


424


exerts pressure on the vent valve


260


(not shown) to maintain the vent valve


260


in a closed position.




To open the vent valves


258


and


260


, the solenoids


426


and


428


are actuated. As illustrated in

FIG. 32

, when the pull-type solenoid


428


is actuated, the piston


444


moves into a retracted position generally in the direction of the arrow


446


. The force of the solenoid


428


overcomes the biasing force of the spring


440


and, thus, the lever


432


moves the actuation pin


424


generally in the direction of the arrow


448


into a retracted position. When the actuation pin


424


is in the retracted position, the vent valve


260


may move upwardly to open and vent gas within the mixing chamber


64


.




Cartridge Sensors




Referring again to

FIG. 18

, a study of the cartridge receptacle


302


reveals that a number of sensors are utilized to monitor and/or control the system


10


in general and the oxygenation device


54


in particular. Due to the nature of the information to be gathered and the types of sensors used to gather this information, the oxygenation device


54


and the sensors include certain features that facilitate the gathering of such information in a more accurate and robust manner. However, it should be appreciated that other types of sensors and/or features may be utilized to gather similarly relevant information for use in monitoring and/or controlling the system


10


and oxygenation device


54


.




As will be appreciated from a detailed discussion of the electronic controls of the system


10


, it is desirable to monitor and control fluid levels within the atomization chamber


62


and the mixing chamber


64


. Accordingly, an AO level sensor


480


is provided to monitor the level of aqueous oxygen within the atomizer chamber


62


, and a high level sensor


482


and a low level sensor


484


are provided to monitor the level of the oxygen-enriched blood within the mixing chamber


64


. As mentioned above, because the oxygenation device


54


is configured as a replaceable cartridge in this exemplary embodiment, the sensors have been placed within the cartridge enclosure


26


instead of within the oxygenation device


54


. Thus, the level sensors


480


,


482


, and


484


do not actually contact the fluid within the chambers


62


and


64


. Were the sensors


480


,


482


, and


484


to contact the liquid, they could become contaminated and, thus, the sensors would typically be replaced each time the system


10


was used for a different patient. Since this would likely add to the cost of replacement items, and potentially affect the sterility of the system, from both a user's standpoint and a patient's standpoint, it is desirable that the sensors do not contact the liquid within the oxygenation device


54


.




In this embodiment, the sensors


480


,


482


, and


484


are ultrasonic sensors. Because ultrasonic waves travel more efficiently through solids and liquids than through air, it is desirable that the sensors


480


,


482


, and


484


and/or the oxygenation device


54


be configured in a manner which promotes the efficient transmission and reception of ultrasonic waves. In this embodiment, both the sensors


480


,


482


, and


484


and the oxygenation device


54


include features which prove advantageous in this regard.





FIGS. 19 and 33

are cross-sectional views of the cartridge enclosure


26


that illustrate the high level sensor


482


and the AO level sensor


480


, respectively. Although the low level sensor


484


is not illustrated in cross-section, it should be understood that its construction is similar to or identical to the construction of the sensors


480


and


482


. Furthermore, detailed views of the sensors


482


and


480


are illustrated in

FIGS. 34 and 35

, respectively, again with the understanding that the sensors


480


,


482


, and


484


are substantially identical in regard to the details shown in these Figs.




To ensure that physical contact is maintained between the oxygenation device


54


and the sensors


480


,


482


, and


484


, the sensors are advantageously biased into contact with the oxygenation device


54


. The sensors


480


,


482


, and


484


actually utilize a spring-biasing technique, although various other types of biasing techniques may be utilized to achieve similar results. In this example, an ultrasonic transducer element


490


is disposed within a channel


492


formed within a sensor body


494


. The sensor body


494


may be formed in any suitable shape, but it is illustrated in this embodiment as being cylindrical. The sensor body


494


is slidably disposed within a sleeve


496


. The sleeve


496


is fixedly disposed in a wall


498


of the cartridge enclosure


26


. For example, the sleeve


496


may have external screw threads


500


so that the sleeve


496


may be screwed into a threaded bore in the wall


498


. To facilitate slidable movement of the sensor body


494


within the sleeve


496


, a bushing


502


may be provided within the sleeve


496


. In this example, the sensor body


494


includes an annular flange


504


that abuts against one end of the bushing


502


in order to limit outward movement of the sensor body


494


. A spring


506


is disposed in the rear portion of the sleeve


496


. The spring


506


abuts against the opposite side of the annular flange


504


to bias the sensor body


494


generally in the direction of the arrow


508


. The bushing


502


may be adhered to, or an integral part of, the sleeve


496


, or it may be held in place by an external seal or cap


510


.




Although the spring-loaded construction of the sensors


480


,


482


, and


484


tends to bias the sensors into contact with the oxygenation device


54


to facilitate the efficient transmission of ultrasonic energy, the nature of the contact between the end of the sensor and the oxygenation device


54


is also important for efficient ultrasonic wave transmission. Hence, to improve this contact region, the sensors


480


,


482


, and


484


include a resilient member


512


, such as a rubber cap. The resilient member


512


is able to deform slightly as it contacts the oxygenation device


54


to ensure that a good contact is made. To enhance the contact region further, the oxygenation device


54


advantageously includes flat contact portions


514


and


516


, respectively, so that the contour of the oxygenation device


54


matches the contour of the resilient member


512


. In addition, to enhance the ultrasonic contact even further, a suitable gel may be used between the oxygenation device


54


and the sensors


480


,


482


, and


484


.




The cartridge enclosure


26


advantageously includes other sensors as well. For example, it may be desirable for the system


10


to be able to determine whether the oxygenation device


54


has been inserted within the cartridge enclosure


26


. To provide this information, a cartridge present sensor


520


may be disposed within the cartridge enclosure


26


. In this example, the cartridge present sensor


520


, as illustrated in

FIG. 19

, may be a reflective infrared sensor that is positioned within an opening


522


in the wall


498


of the cartridge enclosure


26


. Unlike the ultrasonic sensors discussed previously, the efficiency of a reflective infrared sensor is not improved by physical contact. Indeed, the efficiency of a reflective infrared sensor relates more to the nature of the surface reflecting the infrared energy back to the sensor. In other words, if the surface is irregular, the infrared energy transmitted from the infrared sensor may scatter so that little or no infrared energy is reflected back to the sensor. On the other hand, if the surface is smooth, generally perpendicular to the sensor, and/or reflective, it tends to maximize the amount of infrared energy reflected back to the sensor. Accordingly, the portion of the oxygenation device


54


positioned adjacent the cartridge present sensor


520


is advantageously configured to promote reflection of infrared energy back to the cartridge present sensor


520


. In this example, the oxygenation device


54


advantageously includes a flat section


524


to ensure that the cartridge present sensor


520


receives a relatively strong reflective signal so that it can properly indicate whether the oxygenation device


54


is present.




It may also be desirable to monitor the temperature of the aqueous oxygen formed within the atomizer chamber


62


. The temperature of the aqueous oxygen is a useful parameter because the oxygenation level of the aqueous oxygen, and ultimately the oxygenation level of the oxygen-enriched blood, may vary with temperature. If it is desirable to take a temperature measurement into account to monitor and control the functioning of the oxygenation device


54


and the system


10


, the temperature may be sensed in a variety of different areas. For example, a simple room temperature sensor may be incorporated somewhere within the system


10


, using the assumption that the physiologic solution to be oxygenated will typically be at room temperature. Alternatively, the temperature of the oxygenation device


54


may be monitored, using the assumption that the aqueous oxygen within the oxygenation device


54


will be at the same temperature.




However, to provide the greatest level of control, it may be desirable to measure the temperature of the aqueous oxygen within the atomizer chamber


62


. Although a thermocouple could be disposed in the atomizer chamber


62


of the oxygenation device


54


with appropriate electrical contacts extending out of the oxygenation device


54


, the use of a sensor within a disposable device would only increase the cost of the device. Accordingly, it may be desirable to utilize a sensor that is external to the atomizer chamber


62


and yet still able to monitor the temperature of the aqueous oxygen within the atomizer chamber


62


. To achieve this function in this example, an external temperature sensor


540


is coupled within an opening


542


in the wall


498


of the cartridge enclosure


26


as illustrated in FIG.


33


. The temperature sensor


540


may be, for example, a pyroelectric sensor or a piezoelectric sensor. Changes in the temperature of the AO solution within the atomizer chamber


62


will alter the frequencies of such signals and, thus, indicate the actual temperature of the AO solution.




Gas Coupling




The cartridge enclosure


26


also includes another interesting feature regarding the manner in which it interfaces with the oxygenation device


54


. As previously discussed, the oxygenation device


54


includes an oxygen inlet


210


located near the top of the atomizer chamber


62


. As also previously mentioned, a supply of oxygen


60


regulated to about 600 psi is coupled to the oxygen inlet


210


. Thus, it may be desirable to provide a connection to the inlet


210


that effectively handles such pressure and does not require user intervention.




Referring to

FIG. 36

, the oxygen supply


60


is typically enabled by a flow valve


600


. The flow valve


600


delivers oxygen through a pressure transducer


602


and a check valve


604


. The oxygen then proceeds through a tee


606


and into a line


608


. The line


608


is coupled to a plunger


610


illustrated in the cross-sectional view of FIG.


37


. The plunger


610


includes a port


612


that runs laterally from the line


608


and then downwardly into the cartridge cavity


302


. The plunger


610


is slidably disposed within a bushing or sleeve


614


. As best illustrated in the detailed views of

FIGS. 38 and 39

, the sleeve


614


includes a recessed area


616


in which a spring


618


is disposed. The spring tends to bias the plunger


610


upwardly so that the coupling portion


620


of the plunger


610


that is configured to seal against the oxygen inlet


210


of the oxygenation device


54


is recessed slightly.




The top of the plunger


610


includes a slanted or cammed portion


622


that abuts in a complimentary relationship with a slanted or cammed portion


624


of a rod


626


. The rod


626


is slidably disposed within an opening


628


in the cartridge enclosure


26


. The rod


626


is biased in the direction of the arrow


630


in an extended position by a spring


632


. As best illustrated in

FIG. 39

, when a user closes the door


304


, the rod


626


is moved in the direction of the arrow


634


against the bias of the spring


632


. As the rod


626


moves back against the spring


632


, the cammed surfaces


622


and


624


slide against one another, thus forcing the plunger


610


downwardly in the direction of the arrow


636


to seal the coupling portion


620


against the oxygen inlet


210


. The rod


624


is advantageously provided with an adjustment screw


638


. The adjustment screw


638


may be adjusted so that the abutment portion


640


of the rod


626


is in an appropriate position to ensure that the coupling portion


620


of the plunger


610


solidly seals against the oxygen inlet


210


when the door


304


is closed and latched.




Piston Drive Mechanism




To this point in the discussion, all of the various interfaces between the cartridge receptacle


302


and the oxygenation device


54


have been discussed with the exception of one. As mentioned previously, the oxygenation device


54


includes a piston assembly


160


that is configured to draw physiologic solution into the chamber


58


and to deliver it under pressure to the atomization chamber


62


. As illustrated in

FIG. 8

, the plunger


164


includes a key


176


at one end. As mentioned during that discussion, the key


176


is configured to fit within a key slot of a device that moves the piston assembly


160


between its extended and retracted positions.




Although a variety of different mechanisms may be used to achieve this function, the drive mechanism utilized in the present embodiment is illustrated in FIG.


40


and generally designated by the reference numeral


700


. Generally speaking, the drive mechanism


700


includes a ball screw mechanism


702


that is driven and controlled by a motor


704


. In this embodiment, the motor


704


is a stepper motor whose position is monitored by an optical encoder


706


. Although the motor


704


may be directly coupled to the ball screw mechanism


702


, a transmission


708


is used to transfer power from the motor


704


to the ball screw mechanism


702


in this embodiment. Specifically, an output shaft


710


of the motor


704


is coupled to a gear


712


. The gear


712


meshes with a gear


714


that is operatively coupled to turn a screw


716


. In this embodiment, the gears


712


and


714


have a drive ratio of one to one. However, any suitable drive ratio may be used.




As the motor


704


turns the screw


716


, a “drive” assembly


718


rides up or down the screw


716


generally in the direction of the arrow


720


depending upon the direction of rotation of the screw


716


. A ram


722


is slidably disposed about the screw


716


at the top of the drive assembly


718


. The ram


722


includes a key way


724


that is configured to accept the key


176


of the piston assembly


160


. Hence, as the ram


722


moves up and down with the drive assembly


718


in response to rotation of the screw


716


, it moves the piston assembly


160


back and forth within the chamber


58


.




The drive assembly


718


advantageously includes a load cell


726


that is loaded as the ram


722


extends to drive the piston assembly


160


into the chamber


58


. The force exerted on the load cell


726


relates to the fluid pressure within the chamber


58


when the piston assembly


160


is driving fluid out of the passageway


190


. Accordingly, the reading from the load cell


726


may be used to control the speed and position of the ram


722


to ensure that fluid is delivered to the atomization chamber


62


at the desired pressure.




The components of the stepper motor assembly


700


are more clearly illustrated in the exploded view of

FIGS. 41A and 41B

. In addition to the components previously discussed, it can be seen that the gears


712


and


714


ride on respective bearings


730


and


732


. The motor


704


is mounted to one side of a bracket


734


, while a shroud


736


that surrounds the drive assembly


718


is mounted on the other side of the bracket


734


. It can further be seen that the screw


716


is mounted within a coupling


738


that rides on a tapered thrust bearing


740


. The thrust bearing


740


is useful for accommodating the force of thrusting the ram


722


upwardly to drive the piston assembly


160


into the chamber


58


.




The drive assembly


718


includes a nut


742


that is threadably coupled to a load cell mount


744


. Referring additionally to the cross-sectional view of

FIGS. 42 and 43

, the load cell mount


744


includes a slot


746


having a closed end. When the load cell mount


744


is placed within the shroud


736


, the slot


746


is aligned with a set pin


748


. The set pin


748


is disposed within the slot


746


to prevent the drive assembly


718


from bottoming out as it moves downwardly in response to rotation of the screw


716


. Instead, the drive assembly


718


stops when the end of the slot


746


meets the set pin


748


.




It should also be appreciated that the drive assembly


718


should move axially, not rotationally, in response to rotation of the screw


716


. To accomplish such movement, a guide


737


is disposed on the inner wall of the shroud


736


. The guide


737


interfaces with a slot


747


in the load cell mount


744


to prevent rotation of the drive assembly


718


as it moves up and down along the screw


716


. Rather, because the drive assembly


718


is prevented from rotating, it moves axially relative to the screw


716


.




The lower end of the ram


722


includes a flange


750


. The flange


750


impinges upon the top portion of a load cell cover


752


, and a lock ring


754


is coupled to the bottom of the ram


722


to fix the load cell


726


and the load cell cover


752


onto the ram


722


. The load cell cover


752


is further coupled to the load cell mount


744


by a screw


756


. Finally, the upper end of the ram


722


is placed through a bearing


758


, and a cover plate


760


is screwed onto the top of the shroud


736


.




The stepper motor assembly


700


further includes a sensor assembly


800


as illustrated in

FIGS. 44-48

. The sensor assembly


800


provides two signals to the system controller


55


. The first signal is generated when the drive assembly


718


, and thus the piston assembly


160


, has reached its maximum travel, i.e., its maximum extension. The second signal is provided when the drive assembly


718


, and thus the piston assembly


160


, reaches its home position, i.e., maximum retraction. The maximum travel signal is useful to ensure that the cap


166


of the piston assembly


160


does not bottom against the end of the chamber


58


. The home position signal is useful for resetting the optical encoder


706


so that it can start monitoring the motor


704


from a known position of the drive assembly


718


.




As illustrated in

FIGS. 44 and 46

, the sensor assembly


800


includes a maximum travel sensor


802


and a home position sensor


804


. In this embodiment, the sensors


802


and


804


are optical sensors. Thus, as best illustrated in

FIG. 48

, each of the sensors


802


and


804


includes an optical transmitter


806


and an optical receiver


808


. So long as the path between the optical transmitter


806


and optical receiver


808


remains clear, the optical receiver


808


receives the optical signal transmitted from the optical transmitter


806


. However, if an obstruction comes between the optical transmitter


806


and the optical receiver


808


, the optical receiver


808


does not receive the optical signal sent from the optical transmitter


806


. Thus, the output of the optical sensor


802


or


804


will change in this circumstance to indicate that an obstruction is present.




In the present embodiment of the sensor assembly


800


, a tab or flag


810


is coupled to the load cell mount


744


, as best illustrated in FIG.


47


. In this embodiment, screws


812


and


814


are used to couple the flag


810


to the load cell mount


744


, although any suitable mounting arrangement may be utilized.

FIGS. 46 and 47

illustrate the drive assembly


718


in the home position. Accordingly, the flag


810


is positioned between the optical transmitter


806


and the optical receiver


808


of the home position sensor


804


.




General System Operation




Now that the various mechanical components of the system


10


have been discussed, the manner in which the system


10


operates under the control of various electrical components may now be discussed. Turning now to

FIG. 49

, a state diagram


900


depicts the basic operation of this embodiment of the system


10


.




When the system


10


is powered on or reset, it enters an initialization mode


902


. In the initialization mode, the system controller


55


sets various system parameters and performs various diagnostic checks. For example, if the system


10


was powered down improperly the last time it was turned off, an error code may be provided. Furthermore, if the system


10


experiences a watchdog timer failure, which typically means that its processor is lost or not functioning properly, the system will enter a watchdog failure mode


904


.




In the initialization mode


902


, the system controller


55


also reads the cartridge present signal delivered by the sensor


520


. As illustrated in

FIG. 50

, the cartridge present signal is processed by an IO register subsystem


906


prior to processing by the CPU


908


. If an oxygenation device


54


is present within the cartridge enclosure


26


, the system switches from the initialization mode


902


into an unload mode


910


. In the unload mode


910


, the oxygenation device


54


is depressurized and the door is unlocked to allow removal of the oxygenation device


54


. Removal of a used oxygenation device


54


is desirable to ensure that the same oxygenation device


54


is not used for multiple patients. To depressurize the oxygenation device


54


, the system controller


55


delivers an O


2


vent signal


912


to the solenoid


426


associated with the atomizer chamber


62


and a blood mixing chamber vent signal


914


to the solenoid


428


associated with the mixing chamber


64


. As discussed previously, the solenoids


426


and


428


respond by retracting the respective pins


422


and


424


to enable the vent valves


258


and


260


to open. Once the oxygenation device


54


has been depressurized, the system controller


55


disables a door lock signal


916


which causes the solenoid


348


to retract and withdraw the locking pin


342


from the door latch


310


.




If the user does not unload the oxygenation device


54


within 30 seconds, a timeout occurs and the system


10


switches into a wait state


920


, labeled wait mode


3


. In the wait mode


3


state


920


, an unload command will continue to be delivered so that the system


10


switches between the unload mode


910


and the wait mode


3


state


920


until the user has completed the unload operation. Then, when the oxygenation device


54


is not present, the system switches from the wait mode


3


state


920


back into the initialization mode


902


.




Once initialization is complete, the system


10


switches into a wait mode


1


state


922


. In the wait mode


1


state


922


, the system controller


55


monitors a RS


232


serial communications port


924


to await a load command from the host/user interface


66


. Upon receipt of the load command, the system


10


switches into a load mode


926


. The load mode


926


allows a user to install a new oxygenation device


54


and to prepare the system for priming. In the load mode


926


, all valve actuation pins


382


,


384


,


386


,


422


, and


424


, as well as the door lock pin


342


, are retracted. Retraction of the valve actuation pins is desirable because the extended actuation pins may inhibit the oxygenation device from being installed properly within the cartridge enclosure


26


. To retract the respective valve actuation pins


382


,


384


,


386


,


422


, and


424


, as well as the door lock pin


342


, the system controller


55


delivers a fill signal


930


, a flush signal


932


, an AO flow signal


934


, an O


2


vent signal


912


, a blood mixing chamber vent signal


914


, and a lock signal


916


, to the solenoids


388


,


390


,


392


,


426


,


428


, and


348


, respectively.




Like the unload mode


910


described previously, the load mode


926


also includes a timer, such as a 30 second timeout, which causes the system


10


to revert from the load mode


926


back to the wait mode


1


state


922


if the user has not loaded the oxygenation device


54


in the allotted time. However, once the user has successfully loaded the oxygenation device


54


within the cartridge enclosure


26


as indicated by the cartridge present signal


520


, the valve actuation pins


382


,


384


,


386


,


422


, and


424


, as well as the door lock pin


342


, are all extended so that the respective valves


202


,


204


,


206


,


258


, and


260


are held in their closed positions, and so that the latch


310


will lock when the door


304


is closed.




Once the door


304


has been closed and locked, the load operation is complete, and the system


10


switches from the load mode


926


into a wait mode


2


state


940


. In the wait mode


2


state


940


, the system controller


55


monitors the RS232 serial communications port


924


to await either a prime command or an unload command. If the unload command is received, the system


10


transitions into the unload mode


910


, which operates as previously discussed. However, if the prime command is received, the system


10


transitions into a prime mode


942


.




A user initiates the prime mode


942


by pressing the prime switch


108


. In the prime mode


942


, the system


10


fills the fluid supply chamber


58


with physiologic solution and drives the piston assembly


160


to pressurize the solution and transfer it into the atomizer chamber


62


until the appropriate level of fluid is reached. In the prime mode


942


, a stepper motor drive subsystem


950


of the system controller


55


reads the position of the stepper motor


704


from the encoder


706


and drives the stepper motor


704


to cause the ram


722


to push the piston assembly


160


into its fully extended position within the fluid supply chamber


58


. As the piston assembly


160


is retracted, physiologic solution is drawn into the fluid supply chamber


58


through the passageway


144


. The piston assembly


160


then extends again to pressurize the physiologic solution within the fluid supply chamber


58


and to transfer it from the fluid supply chamber


58


into the atomizer chamber


62


. In this mode, the fill valve


202


is opened, so that the fluid enters the atomizer chamber


62


through the tube


232


rather than through the atomizer


216


.




When the system controller


55


receives the signal from the AO level sensor


480


indicating that the atomizer chamber


62


has been appropriately filled, the stepper motor driver subsystem


950


retracts the piston assembly


160


to the home position and then extends the piston assembly


160


to transfer an additional amount of solution, e.g., 3 ccs, into the atomizer chamber


62


. After the atomizer chamber


62


has been primed with the physiologic solution, the system controller


55


delivers an O


2


flow signal


952


to an O


2


flow solenoid


954


to open a valve


956


and allow the oxygen from the supply


60


to pressurize the atomizer chamber


62


.




Once the proper level of fluid has been reached, the prime mode


942


is complete. However, prior to completion of the priming operation, the system


10


may transfer from the prime mode


942


to the wait mode


2


state


940


if the priming operation is interrupted by a halt command transmitted as either a result of an error in the priming operation or as a result of the user pressing the stop switch


112


.




Once the prime mode


942


is complete, the system


10


transitions into an AO off mode


960


. While in the AO off mode


960


, no aqueous oxygen is produced or delivered. Instead, the system controller


55


delivers a flush signal


932


to the solenoid


390


to open the flush valve


204


. As previously discussed, when the flush valve


204


is open, physiologic solution flows from the fluid supply chamber


58


through the valve assembly


200


and into the mixing chamber


64


through the capillary tube


246


. This mode of delivery continues so long as the blood flow through the mixing chamber


64


is above a predetermined rate, e.g., 50 ml per minute. If the blood flow drops below the predetermined rate, the system


10


transitions into a timeout mode


962


. In the timeout mode


962


, the system


10


does not flow, fill, or flush, and the piston assembly


160


returns to the home position. The system


10


will transition from the timeout mode


962


to the unload mode


910


if either the unload command is received from the host/user interface or if the system


10


has been in the timeout mode


962


for a predetermined time, e.g., 150 seconds. However, once blood flow rises above the predetermined rate, the system transitions from the timeout mode


962


back to the AO off mode


960


.




When the AO on command is received, the system


10


transitions from the AO off mode


960


to an AO on mode


964


. The AO on command is produced when the user presses the prime button


108


and the start button


110


simultaneously. In the AO on mode


964


, the priming signal is delivered from the blood pump system


24


on a line


966


to the interlock system


44


. If the system controller


55


is in the AO off mode


960


when the prime command is received, then the logic block


134


of the interlock system


44


delivers an enable signal on line


126


to enable the blood pump


24


. The logic block


134


also delivers a draw clamp signal on a line


970


to the draw clamp


78


to open it while the return clamp


80


remains closed. The logic block


130


also delivers a prime signal on a line


968


to the CPU


908


of the system controller


55


. In response to receiving the prime signal, the system controller


55


monitors the low level sensor


484


to determine when enough blood has flowed into the mixing chamber


64


for the chamber to be filled to the level indicated by the low level sensor


484


. The low level signal is also sent to the logic block


134


of the interlock system


44


via a line


974


. When the interlock system


44


determines that the chamber


64


has been filled to the level indicated by the low level sensor


484


, it delivers a return clamp signal on a line


972


to the return clamp


80


to open it. Simultaneously, the system controller


55


delivers a cyclox vent signal


914


to the solenoid


428


in order to close the vent valve


260


.




The system


10


continues to operate in the AO on mode


964


in this manner unless blood flow drops below a predetermined rate, e.g., 50 ml. per minute. In this instance, the system


10


will transfer from the AO on mode


964


to the unload mode


910


, which will operate as discussed previously.




The logic block


134


of the interlock system


44


also delivers an AO enable signal on a line


976


to the CPU


908


of the system controller


55


. The AO enable signal causes the system controller


55


to deliver an AO flow signal


934


to the solenoid


392


to open the flow valve


206


. As discussed previously, with the flow valve


206


opened, aqueous oxygen flows from the atomizer chamber


62


through the capillary tube


246


and into the mixing chamber


64


to be mixed with the blood.




Bubble Detector




As mentioned previously, the system


10


advantageously includes a bubble detector


74


that interfaces with a bubble sensor


76


to monitor the oxygen-enriched blood in the return tube


50


for bubbles. An exemplary embodiment of the bubble detector


74


is illustrated in FIG.


51


. The bubble detector


74


includes a digital signal processor (DSP)


1000


that operates under software control to perform many of the functions of the bubble detector


74


. The bubble detector


74


receives a return pressure signal and a flow rate signal from the interlock system


44


on lines


1002


and


1004


, respectively. An analog-to-digital converter (ADC)


1006


receives these analog signals and converts them to digital signals. These digital signals are transmitted from the ADC


1006


to a microcontroller


1008


. The microcontroller


1008


also receives user input from an RS-232 serial communications port


1010


from the host/user interface


66


, as well as an initiate signal on line


1012


from the interlock system


44


.




The DSP


1000


and the microcontroller


1008


interface with one another via interface and control logic


1014


. Based on inputs from the DSP


1000


and the microcontroller


1008


, the interface and control logic


1014


delivers a transducer driver signal on line


1016


to a transducer driver


1018


. In response, the transducer driver


1018


delivers a signal to the transducer


76


via line


1020


. As illustrated in

FIG. 52

, the transmitted signal delivered by the transducer


76


includes bursts of high frequency pulses


1023


A and


1023


B. Each pulse burst may include 20 pulses for instance at 3.6 MHz, with microseconds between bursts. A return signal from the transducer


76


is received on the line


1022


. The signal received from the transducer


76


on line


1022


resembles the transmitted signal


1021


, but it is shifted later in time and has a smaller amplitude. It typically takes longer than one burst period for a bubble to pass by the transducer


76


. Therefore, each bubble may be sampled each time a pulse is delivered during the burst period, e.g., in this example, each bubble may be sampled 20 times as it travels past the transducer


76


.




The strength of the received signal on the line


1022


relative to the transmitted signal on the line


1020


provides information regarding the presence of bubbles within the return tube


50


. As illustrated in

FIG. 54

, the bubble sensor


76


includes an ultrasonic transmitter


1040


and an ultrasonic receiver


1042


. The bubble sensor


76


is advantageously disposed on the outside of the return tube


50


. Thus, the ultrasonic signal from the transmitter


1040


is transmitted through the return tube


50


, as well as any fluid within the return tube


50


, to the receiver


1042


. If the fluid in the return tube


50


contains no bubbles, the ultrasonic signal propagates from the transmitter


1040


to the receiver


1042


in a relatively efficient manner. Thus, the signal strength of the return signal delivered by the receiver


1042


on the line


1022


is relatively strong. However, if the fluid within the return tube


50


contains bubbles


1044


, as illustrated in

FIG. 55

, the ultrasonic signal received by the receiver


1042


will be attenuated. The attenuated transmission of the ultrasonic signal across fluid containing bubbles results from the fact that the bubbles


1044


tend to scatter the ultrasonic signal so that less of the transmitted signal is ultimately received by the receiver


1042


.




As illustrated by way of example in

FIG. 53

, the first peak


1027


A depicts a signal that was transmitted through fluid containing no bubbles, and the second peak


1027


B depicts a signal that was transmitted through fluid containing bubbles. The relative weakness of the peak


1027


B is demonstrated by a reduction in the peak


1027


B. The attenuation of peak


1027


B is related to the diameter of the bubble passing through the bubble sensor


76


at the time the signal was transmitted. Specifically, the attenuation in the signal is related to the bubble's cross-sectional area and thus square of the diameter of the bubble, so that the square root of the signal is directly proportional to the bubble diameter.




To facilitate processing of the return signal, it is delivered to a signal conditioner


1024


. The signal conditioner


1024


amplifies and filters the return signal. The signal conditioner


1024


then detects the amount of ultrasonic energy of the signal and transmits it to an analog to digital converter (ADC)


1026


. A signal


1025


delivered to the ADC


1026


is illustrated in FIG.


53


. As can be seen from a study of the signal


1025


, each of the high frequency pulse trains


1023


A and


1023


B now resembles a single peak


1027


A and


1027


B, respectively. The ADC


1026


samples only the peaks


1027


A and


1027


B in the amplitude signal


1025


. In this example, each peak


1027


A and


1027


B is approximately 6.6 microseconds in width, and the ADC


1026


samples


128


peaks to establish


128


data points.




The digitized output of the ADC


1026


is delivered to a buffer, such as a first-in/first-out (FIFO) buffer


1030


. The buffer


1030


stores the digitized representations of 128 peaks and delivers them one by one to the DSP


1000


. The interface and control logic


1014


controls delivery of the signals from the buffer


1030


to the DSP


1000


.




The DSP


1000


reads the data points for each of the digitized peaks and sums them together. The sum of the digitized peaks correlates to the amount of ultrasonic energy received. In this embodiment, the DSP


1000


maintains a running average of the sum of the last 16,000 or more peaks. The current sum is subtracted from the average to provide a high pass filter which effectively removes any DC offset. The DSP


1000


also performs a low pass filter operation by convolving the resulting signal through an FIR array. In this example, the FIR array is a 64 point array. The filtering is performed to ensure that the bubbles are discriminated from the noise in the signals. The resulting signals of different sized bubbles is illustrated in FIG.


61


.




Once the DSP


1000


determines the diameter of each bubble detected, it calculates the volume of the bubble. However, it should be understood that the volume of the bubble delivered to the patient


38


is affected by the pressure of the fluid within the return tube


50


. Because the pressure of the fluid within the return tube


50


is typically higher, e.g., approximately two to three atmospheres, as compared to the blood within the patient's vessels, e.g., approximately one atmosphere, a conversion is advantageously performed to determine the volume of the bubble once it reaches the patient


38


. Since the pressure in the return tube


50


is delivered to the bubble detector


74


on the line


1002


, and since the pressure of the patient's blood can be assumed to be one atmosphere using the ideal gas law, the volume of the bubble at the patient equals V


p


=(P


s


·V


s


)/P


a


, where V


p


, is the volume of the bubble at the patient


38


, P


s


is the pressure at the bubble sensor


76


, V


s


is the volume of the bubble at the bubble sensor


76


, and P


a


is atmospheric pressure.




The DSP


1000


advantageously places bubbles of certain sizes in appropriate “bins” or categories. In other words, the DSP


1000


may maintain different categories of bubble sizes. For example, the categories may include sixteen bins of 75 micron diameter increments. The number of bubbles in each category may be transmitted to the display


32


so that a user can monitor the number and size of bubbles being produced during the surgical procedure. The number and size of bubbles also may be monitored by the bubble detector


74


or elsewhere within the system


10


to monitor the operation of the system


10


.




The bubble detector


74


also may accumulate total volume of all bubbles detected over time. If the accumulated volume exceeds a prescribed limit within a prescribed time, then operation of the system


10


may be altered. For example, if the total volume of bubbles exceeds 10 microliters in a 90 minute period, the bubble detector


74


may deliver a “request to stop” signal on a line


1050


. In this embodiment, the request to stop signal is received by the interlock system


44


, so that the interlock system


44


can shut down the system


10


as previously described. Since most patients typically resolve small volumes of gas over time, the running total may be decremented as the procedure progresses so that the predetermined limit which triggers shut down of the system


10


will not be reached as rapidly. In addition, prior to reaching the predetermined limit, the bubble detector


74


may provide an early warning of an impending shut down so that the system controller


55


can lower the pO


2


level of the blood in the return tube


50


to curtail bubble production and, thus, avoid shutdown.




Bubble Detector Evaluation or Calibration




Individual ultrasonic probes may have varying degrees of resolution. Therefore, a limitation on the bubble detector's ability to detect bubbles may arise when the size and/or velocity of some bubbles are beyond the resolution of the probe. Depending on the circumstances, it is possible that microbubbles (bubbles with diameters of about 50 μm to about 1000 μm) and/or macrobubbles (bubbles with diameters greater than 1000 μm) may escape detection. When bubbles escape detection, the accuracy of the bubble detector may be compromised.




Thus, it may be desirable to utilize a system and method for evaluating the bubble detection capabilities of a bubble detector. The system and method of evaluation described below is capable of determining the microbubble and macrobubble reolution of the bubble detector at a plurality of flow rates and material viscosities. Generally speaking, bubbles of a determinable size are introduced into a flow material. The size and quantity of bubbles introduced into the flow material are measured by the bubble detector under evaluation. Thereafter, the size and quantity of bubbles introduced into the flow material are determined independently.




An exemplary embodiment of a calibration and evaluation system


1105


for bubble detectors, such as the bubble detector


74


, is illustrated in FIG.


56


. The system and method permits a practitioner to control the bubble size, rate of bubble production, and the rate of flow of flow material. The system


1105


employs a containment vessel


1110


for storing a flow material


1112


. The vessel


1110


includes an inlet


1116


and outlet


1118


so that the flow material


1112


travels generally in the direction of the arrow


1119


. A pump


1120


, such as a peristaltic pump, is utilized to induce and maintain a desired flow rate. Advantageously, the pump


1120


is capable of transmitting the flow material


1112


at a plurality of flow rates. Flow materials


1112


of varying viscosity may be utilized and may include newtonian or non-newtonian fluids. Typically, the viscosity of the flow material


1112


used for evaluation is comparable with the viscosity of the material utilized in the operational environment, e.g., blood mixed with gas-enriched physiologic fluid in this example.




The system


1105


employs a first conduit


1130


, typically of predetermined internal diameter and predetermined length, having a proximal end


1132


and distal end


1134


, through which the flow material


1112


may be passed at various rates. The proximal end


1132


is coupled to the outlet


1118


to receive the flow material


1112


from the vessel


1110


. The distal end


1134


is coupled to a connecting device


1140


. The connecting device


1140


, for example a T-connector, is typically positioned along the longitudinal axis of the first conduit


1130


and in fluid communication therewith to permit the continued unimpeded flow of the flow material


1112


.




A bubble-forming device


1143


may be used to induce bubble formation in the flow material


1112


through the introduction of a bubble-forming material


1150


. The bubble-forming material


1150


typically includes a gas, such as air. The flow material


1112


may contain a surfactant, such as sodium dodecyl sulfate (SDS), to promote bubble formation and retention.




As best illustrated in

FIGS. 57 and 58

, the bubble-forming device


1143


in this example includes a bubble-forming capillary


1144


, which is typically of predetermined internal diameter and predetermined length. The capillary


1144


has a proximal end


1146


and a distal end


1148


. The proximal end


1146


is attached by a bubble-forming lumen


1153


to a bubble-pumping device


1155


, such as a syringe. The bubble-pumping device


155


is typically capable of injecting the bubble-forming material


1150


into the flow material


1112


at various injection rates. The distal end


1148


of the capillary


1144


is slidably arranged to be located within the interior of the connecting device


1140


incident to the flow material


1112


, thus resulting in the generation of bubbles within the flow material


1112


. In this example, the capillary


1144


is positioned perpendicular or nearly perpendicular to the longitudinal axis of the direction of flow of the flow material


1112


so that the resultant shear force of the flow generates bubbles of a uniform size at a constant rate.




Bubble size may be regulated by the internal diameter of the capillary


1144


or by positioning the distal portion


1148


of the capillary


1144


at various positions within the material flow. Increasing the internal diameter of capillary


1144


increases bubble size. Similarly, positioning the distal portion


1148


of the capillary


1144


away from the longitudinal axis of the flow material


1112


increases bubble size. The rate of bubble formation may be varied by increasing or decreasing the flow rate of the bubble-forming material


1150


introduced into the flow material


1112


. For example, an increase in the flow rate of the bubble-forming material


1150


increases the rate of bubble formation in the flow material


1112


.




The system


1105


further employs a second conduit


1170


, which is typically of predetermined internal diameter and predetermined length. A proximal end


1172


of the second conduit


1170


is coupled to the connecting device


1140


, and a distal end


1174


of the second conduit


1170


is coupled to the inlet


1116


of the containment vessel


1110


. To maintain a substantially constant flow rate in the conduits


1130


and


1170


, the second conduit


1170


is usually coaxially aligned with the first conduit


1130


, and the diameter of the second conduit


1170


is usually equivalent to the diameter of the first conduit


1130


. The probe


76


of the bubble detector


74


to be evaluated is positioned proximal to the second conduit


1170


to enable detection of bubbles within the flow material


1112


passing through the second conduit


1170


.




The connecting device


1140


may be optically transparent to permit visual inspection of the bubble generation process. Indeed, a recording device


1160


, such as a CCD camera, may be focused on the distal end


1148


of the capillary


1144


to observe and record the size and quantity of bubbles within the flow material


1112


. Thus, bubble detectors, such as the bubble detector


74


for example, may be calibrated by comparing the size and quantity of bubbles detected by the probe


76


with the size and quantity of the bubbles measured by the recording device


1160


. A second examining device (not shown) may be positioned along second conduit


1170


between the bubble detector probe


76


and the inlet


1116


of the containment vessel


1110


to provide the practitioner access to the flow material


1112


.




In operation, flow is initiated by activating the pump


1120


. The flow rate of the flow material


1112


is permitted to stabilize before introducing bubbles to the system


1105


. Once the system


1105


has stabilized, bubbles are introduced to the flow material


1112


by activating the bubble-forming device


1143


. The system


1105


is permitted to stabilize once again before calibrating the bubble detector


74


.




The microbubble resolution of the bubble detector


74


may be determined by introducing bubbles of successively smaller diameters in successive tests. The macrobubble resolution of the bubble detector


74


may be determined in a similar manner by introducing bubbles of successively larger diameters in successive tests. Once the rate of bubble generation and flow rate have stabilized, the recording device


1160


is activated to record the rate of bubble generation and the size of the bubbles generated. The bubble detector


74


to be evaluated is activated for a predetermined amount of time.




The probe


76


examines the bubbles which are generally of known size and quantity, and the probe


76


delivers corresponding signals to the bubble detector


74


. The size and quantity of bubbles recorded by the bubble detector


74


are compared to the size and quantity of the bubbles recorded by the recording device


1160


. Typically, such comparison is performed at a plurality of signal strengths and bubble sizes. Thereafter, one skilled in the art of mathematics may graphically represent this relationship and extrapolate the projected signal strengths at a plurality of bubble sizes. When the signal-to-bubble size relation is graphically plotted, one skilled in the art of mathematics can calculate one or more calibration constants based on the fit of the signal strength to bubble size relationship. The calibration constant(s) can be programmed into the bubble detector


74


to calibrate the bubble detector


74


.




An alternative embodiment of the calibration and evaluation system


1105


is identical to the previously described system except for the incorporation of a pulse dampener


1180


, as illustrated in FIG.


59


. The pulse dampener


1180


reduces or eliminates pressure oscillations produced by the pump


1120


. In addition, relatively large bubbles that may be recirculated within the flow circuit become trapped within the pulse dampener


1180


so that they do not disturb the controlled formation of bubbles by the bubble-forming device


1143


.




As shown with further reference to

FIG. 60

, the pulse dampener


1180


comprises a vessel body


1181


having an inlet


1182


and an outlet


1184


. The inlet


1182


is coupled in the first conduit


1130


between the pump


1120


and the connecting device


1140


. The pump


1120


forces the flow material


1112


into the vessel body


1181


through the inlet


1182


. The pressure exerted by the pump


1120


is maintained within the vessel body


1181


, thus forcing the flow material


1112


through the outlet


1184


. Thus, any bubbles produced by the pump


1120


are trapped prior to reaching the connecting device


1140


.




While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.



Claims
  • 1. A system for enriching a bodily fluid with a gas, the system comprising: a pump system adapted to transmit a bodily fluid from a patient; a gas-enriching device operatively coupled to the pump system to receive the bodily fluid, the gas-enriching device combining the bodily fluid with a gas to form a gas-enriched bodily fluid; a bubble detector arranged to detect bubbles in the gas-enriched bodily fluid; a controller adapted to control the pump system and the gas-enriching device automatically; an enrichment device to form a gas-enriched physiologic fluid, and a mixing device to mix the gas-enriched physiologic fluid with the bodily fluid to form the gas-enriched bodily fluid; and wherein the enrichment device comprises an atomizing chamber adapted to receive the gas through a gas inlet, and an atomizer disposed within the atomizing chamber, the atomizer adapted to receive physiologic fluid and to atomize the physiologic fluid upon delivery into the atomizing chamber to form the gas-enriched physiologic fluid.
  • 2. The system, as set forth in claim 1, wherein the pump system comprises:a pump adapted to pump the bodily fluid through a tube; and a flow meter adapted to sense flow of the bodily fluid through the tube, the flow meter generating an actual flow rate signal correlative to flow through the tube, wherein the controller is operatively coupled to the pump and to the flow meter, the controller adapted to receive the actual flow rate signal and to control the pump to maintain a desired rate of flow through the tube.
  • 3. The system, as set forth in claim 2, wherein the pump comprises:a peristaltic pump.
  • 4. The system, as set forth in claim 2, wherein the flow meter comprises:a flow transducer adapted to be operatively coupled to the tube, the flow transducer adapted to deliver to the flow meter a flow signal correlative to flow through the tube.
  • 5. The system, as set forth in claim 2, comprising:a flow setting device operatively coupled to the pump to set the desired rate of flow through the tube.
  • 6. The system, as set forth in claim 5, wherein the flow setting device comprises:a display illustrating the desired flow rate; and a user-actuatable input operatively coupled to the display to adjust the desired flow rate illustrated by the display.
  • 7. The system, as set forth in claim 5, wherein the flow setting device comprises:a personality module having a memory adapted to store the desired flow rate and to deliver the desired flow rate signal to the controller.
  • 8. The system, as set forth in claim 7, wherein the desired flow rate stored in the personality module comprises a desired range of flow rates.
  • 9. The system, as set forth in claim 1, wherein the gas-enriching device comprises a disposable cartridge adapted to be placed in an enclosure.
  • 10. The system, as set forth in claim 9, wherein the cartridge comprises:a housing; an enrichment device disposed in the housing to form a gas-enriched physiologic fluid; and a mixing device disposed in the housing to mix the gas-enriched physiologic fluid with the bodily fluid to form the gas-enriched bodily fluid.
  • 11. The system, as set forth in claim 10, wherein the enrichment device comprises:an atomizing chamber adapted to receive the gas through a gas inlet; and an atomizer disposed within the atomizing chamber, the atomizer adapted to receive physiologic fluid and to atomize the physiologic fluid upon delivery into the atomizing chamber to form the gas-enriched physiologic fluid.
  • 12. The system, as set forth in claim 10, wherein the mixing device comprises:a mixing chamber having a fluid inlet and a fluid outlet; and a fluid delivery device disposed within the mixing chamber in a predetermined relationship with the fluid inlet, the fluid delivery device adapted to receive the gas-enriched physiologic fluid from the atomizing chamber and to deliver the gas-enriched fluid into the mixing chamber to mix with the bodily fluid entering the mixing chamber through the fluid inlet to form the gas-enriched bodily fluid.
  • 13. The system, as set forth in claim 10, wherein the cartridge comprises:a fluid supply device disposed in the housing to supply a physiologic fluid to the enrichment device.
  • 14. The system, as set forth in claim 13, wherein the fluid supply device comprises:a fluid supply chamber having a fluid inlet and a fluid outlet; and a pump disposed within the fluid supply chamber, the pump adapted to draw a physiologic fluid into the fluid supply chamber through the fluid inlet in the fluid supply chamber and to deliver the physiologic fluid to the enrichment device through the fluid outlet in the fluid supply chamber.
  • 15. The system, as set forth in claim 13, wherein the cartridge comprises:a valve assembly disposed in the housing, the valve assembly having valves to control flow of the physiologic fluid between the fluid supply device and the enrichment device and to control flow of the gas-enriched physiologic fluid between the enrichment device and the mixing device.
  • 16. The system, as set forth in claim 10, wherein the enclosure comprises:a receiving chamber sized to accept the cartridge therein; a first level sensor arranged to determine fluid level in the enrichment device; a second level sensor arranged to determine a low fluid level in the mixing device; and a third level sensor arranged to determine a high fluid level in the mixing device.
  • 17. The system, as set forth in claim 15, wherein the enclosure comprises:a receiving chamber sized to accept the cartridge therein; and a valve actuation assembly adapted to actuate the valves of the valve assembly.
  • 18. The system, as set forth in claim 9, wherein the enclosure comprises:a door having a lock to secure the cartridge within the enclosure.
  • 19. The system, as set forth in claim 1, wherein the bubble detector comprises:an ultrasonic transducer pair comprising a transmitting transducer and a receiving transducer, the ultrasonic transducer pair being positionable to sense bubbles in a fluid flow; a transducer driver operatively coupled to the transmitting transducer to cause the transmitting transducer to deliver a pulsed ultrasonic signal across the fluid flow to the receiving transducer; a signal conditioner operatively coupled to the receiving transducer to receive the pulsed ultrasonic signal from the receiving transducer, the signal conditioner conditioning the pulsed ultrasonic signal to produce a conditioned signal; and a signal processor operatively coupled to the signal conditioner to receive the conditioned signal, the signal processor determining information correlative to bubbles in the fluid flow in response to the conditioned signal.
  • 20. The system, as set forth in claim 19, wherein the pulsed ultrasonic signal delivered by the transmitting transducer comprises a frequency range of 3 MHz to 4 MHz and a pulse rate of about 3 KHz to 40 KHz.
  • 21. The system, as set forth in claim 19, wherein the signal conditioner comprises:a detector adapted to detect the amount of ultrasonic energy of the pulsed ultrasonic signal received by the receiving transducer.
  • 22. The system, as set forth in claim 19, wherein the signal conditioner comprises:an analog-to-digital converter adapted to convert the amount of ultrasonic energy detected by the detector into a digital signal.
  • 23. The system, as set forth in claim 19, wherein the signal processor comprises a buffer adapted to hold multiple digital signals.
  • 24. The system, as set forth in claim 23, wherein a reduction in the digital signal as compared to previously recorded digital signals or an average of previously recorded digital signals is correlative to bubbles in the fluid flow.
  • 25. The system, as set forth in claim 19, wherein the signal processor comprises a digital signal processor.
  • 26. The system, as set forth in claim 25, wherein the digital signal processor is adapted to detect and count each bubble in the fluid flow.
  • 27. The system, as set forth in claim 25, wherein the digital signal processor determines the volume of each bubble in the fluid flow.
  • 28. The system, as set forth in claim 27, wherein the digital signal processor converts the volume of each bubble in the fluid flow to a volume of each bubble when it reaches a patient.
  • 29. The system, as set forth in claim 25, wherein the digital signal processor determines an accumulated volume of bubbles in the fluid flow over a given period of time.
  • 30. The system, as set forth in claim 29, wherein the signal processor initiates the stop signal in response to the accumulated volume of bubbles exceeding a predetermined limit, the stop signal being delivered to the controller to cause the controller to cease operation of the pump system and the gas-enriching device.
  • 31. The system, as set forth in claim 1, wherein the controller comprises:a first sensor assembly arranged to monitor the pump system, the first sensor assembly delivering at least one first signal correlative to operation of the pump system; a second sensor assembly arranged to monitor the gas-enriching device, the second sensor assembly delivering at least one second signal correlative to operation of the gas-enriching device; a signal processor operatively coupled to the first sensor assembly and to the second sensor assembly to receive the at least one first signal and the at least one second signal, the signal processor delivering at least one pump system control signal in response to the at least one first signal, the pump system adjusting its operation in response to receiving the at least one pump system control signal from the signal processor, and the signal processor delivering at least one gas-enrichment control signal in response to the at least one second signal; and an actuation assembly arranged to adjust operation of the gas-enriching device in response to receiving the at least one gas-enrichment signal from the signal processor.
  • 32. The system, as set forth in claim 31, wherein the first sensor assembly comprises:a flow transducer adapted to be operatively coupled to a tube carrying the bodily fluid, wherein the at least one first signal comprises a flow signal delivered from the flow transducer, the flow signal being correlative to flow through the tube.
  • 33. The system, as set forth in claim 32, wherein the signal processor comprises a comparison device adapted to receive the flow signal and to compare the flow through the tube to the desired flow range.
  • 34. The system, as set forth in claim 33, wherein the signal processor delivers an enable signal to the pump system in response to the flow signal being indicative of flow through the tube being within a desired flow range.
  • 35. The system, as set forth in claim 33, wherein the signal processor delivers a disable signal to the pump system in response to the flow signal being indicative of flow through the tube being outside the desired flow range.
  • 36. The system, as set forth in claim 33, comprising:a first clamp adapted to be operatively coupled to a draw side of the tube; and a second clamp adapted to be operatively coupled to a return side of the tube, wherein the signal processor closes the first clamp and the second clamp in response to the flow signal being outside the desired flow range.
  • 37. The system, as set forth in claim 31, wherein the gas-enriching device comprises a cartridge adapted to be disposed in an enclosure,wherein the cartridge comprises:a housing; a fluid supply device disposed in the housing to supply a physiologic fluid; an enrichment device disposed in the housing and operatively couple to receive the physiologic fluid from the fluid supply device, the enrichment device converting the physiologic fluid to a gas-enriched physiologic fluid; a mixing device disposed in the housing and operatively coupled to receive the gas-enriched physiologic fluid from the enrichment device and to receive the bodily fluid from the pump system, the mixing device adapted to mix the gas-enriched physiologic fluid with the bodily fluid to form the gas-enriched bodily fluid; and a valve assembly disposed in the housing, the valve assembly having valves to control flow of the physiologic fluid between the fluid supply device and the enrichment device and to control flow of the gas-enriched physiologic fluid between the enrichment device and the mixing device; and wherein the second sensor assembly comprises:a transducer arranged to determine physiologic fluid supplied by the fluid supply device; a first level sensor arranged to determine fluid level in the enrichment device; a second level sensor arranged to determine a low fluid level in the mixing device; and a third level sensor arranged to determine a high fluid level in the mixing device; and wherein the actuation assembly comprises:a valve actuation assembly disposed in the enclosure and adapted to actuate the valves of the valve assembly.
  • 38. The system, as set forth in claim 2, wherein:the bodily fluid is blood; the pump is a blood pump; and the system forms an automated blood pump circuit.
  • 39. The circuit, as set forth in claim 38, wherein the blood pump comprises:a peristaltic pump.
  • 40. The circuit, as set forth in claim 38, wherein the flow meter comprises:a flow transducer adapted to be operatively coupled to the tube, the flow transducer adapted to deliver to the flow meter a flow signal correlative to blood flow through the tube.
  • 41. The circuit, as set forth in claim 38, comprising:a flow setting device operatively coupled to the blood pump to set a desired rate of blood flow through the tube.
  • 42. The circuit, as set forth in claim 41, wherein the flow setting device delivers a desired flow rate signal to the controller, and wherein the controller automatically adjusts the actual rate of flow through the tube to the desired flow rate in response to the desired flow rate signal and the actual flow rate signal.
  • 43. The circuit, as set forth in claim 42, wherein the flow setting device comprises:a display adapted to generate the desired flow rate signal correlative to the desired rate of blood flow through the tube.
  • 44. The circuit, as set forth in claim 43, wherein the display comprises:a digital panel illustrating the desired flow rate; and a user-actuatable input operatively coupled to the digital panel to adjust the desired flow rate illustrated by the digital panel.
  • 45. The circuit, as set forth in claim 42, wherein the flow setting device comprises:a personality module having a memory adapted to store the desired flow rate and to deliver the desired flow rate signal to the controller.
  • 46. The circuit, as set forth in claim 45, wherein the desired flow rate stored in the personality module comprises a desired range of flow rates.
  • 47. The circuit, as set forth in claim 41, wherein the tube has a draw portion for drawing blood from a patient and a return portion for returning blood to a patient, the circuit comprising:a draw tube clamp operatively coupled to the draw portion of the tube, the draw tube clamp being moveable between a clamped position and an unclamped position; a return tube clamp operatively coupled to the return portion of the tube, the return tube clamp being moveable between a clamped position and an unclamped position; and wherein the controller is operatively coupled to the draw tube clamp and the return tube clamp, the controller adapted to move the draw tube clamp and the return tube clamp between the respective clamped and unclamped positions.
  • 48. The circuit, as set forth in claim 47, wherein the blood pump circuit comprises:an extracorporeal circuit.
US Referenced Citations (107)
Number Name Date Kind
2474665 Guarino Jun 1949 A
3142296 Love Jul 1964 A
3437450 Greenwood Apr 1969 A
3512517 Kadish et al. May 1970 A
3721231 Hubert Mar 1973 A
3881483 Sausse May 1975 A
3927981 Viannay et al. Dec 1975 A
4008047 Petersen Feb 1977 A
4041180 Wilson Aug 1977 A
4122858 Schiff Oct 1978 A
4205042 Lobdell et al. May 1980 A
4239729 Hasegawa et al. Dec 1980 A
4297318 Raible Oct 1981 A
4317731 Roberts, Jr. et al. Mar 1982 A
4401431 Arp Aug 1983 A
4442843 Rasor et al. Apr 1984 A
4445896 Gianturco May 1984 A
4466804 Hino Aug 1984 A
4493692 Reed Jan 1985 A
4596210 Schmidtke Jun 1986 A
4602987 Bonaventura et al. Jul 1986 A
4610661 Possis et al. Sep 1986 A
4657756 Rasor et al. Apr 1987 A
4664680 Weber May 1987 A
4666668 Lidorenko et al. May 1987 A
4681119 Rasor et al. Jul 1987 A
4686085 Osterholm Aug 1987 A
4735750 Damann Apr 1988 A
4769241 Heldebrandt et al. Sep 1988 A
4804358 Karcher et al. Feb 1989 A
4808378 Nakanishi et al. Feb 1989 A
4828543 Weiss et al. May 1989 A
4871450 Goodrich et al. Oct 1989 A
4874509 Bullock Oct 1989 A
4874581 Sutherland et al. Oct 1989 A
4917667 Jackson Apr 1990 A
4919895 Heldebrandt et al. Apr 1990 A
4968483 Muller et al. Nov 1990 A
4973558 Wilson et al. Nov 1990 A
5006352 Zelenák née Zoltai et al. Apr 1991 A
5039482 Panzani et al. Aug 1991 A
5069661 Trudell Dec 1991 A
5084011 Grady Jan 1992 A
5086620 Spears Feb 1992 A
5110548 Montevecchi May 1992 A
5152964 Leonard Oct 1992 A
5158533 Strauss et al. Oct 1992 A
5158540 Wijay et al. Oct 1992 A
5180364 Ginsburg Jan 1993 A
5186713 Raible Feb 1993 A
5195971 Sirhan Mar 1993 A
5261875 Spears Nov 1993 A
5277176 Habashi et al. Jan 1994 A
5322500 Johnson et al. Jun 1994 A
5334142 Paradis Aug 1994 A
5356388 Spetka et al. Oct 1994 A
5368555 Sussman et al. Nov 1994 A
5380307 Chee et al. Jan 1995 A
5382407 Leonard Jan 1995 A
5407426 Spears Apr 1995 A
5413558 Paradis May 1995 A
5569180 Spears Oct 1996 A
5573505 Johnson et al. Nov 1996 A
5591399 Goldman et al. Jan 1997 A
5599296 Spears Feb 1997 A
5670094 Sasaki et al. Sep 1997 A
5690831 Kenley et al. Nov 1997 A
5693017 Spears et al. Dec 1997 A
5695717 Polaschegg et al. Dec 1997 A
5709654 Klatz et al. Jan 1998 A
5725492 Igo et al. Mar 1998 A
5730330 Reading Mar 1998 A
5730698 Fischell et al. Mar 1998 A
5730935 Spears Mar 1998 A
5735934 Spears Apr 1998 A
5752929 Klatz et al. May 1998 A
5766490 Taylor et al. Jun 1998 A
5797874 Spears Aug 1998 A
5797876 Spears et al. Aug 1998 A
5814004 Tamari Sep 1998 A
5814222 Zelenák et al. Sep 1998 A
5834519 Spears Nov 1998 A
5843307 Faivre et al. Dec 1998 A
5849191 Agranonik et al. Dec 1998 A
5871093 Eliaz et al. Feb 1999 A
5879282 Fischell et al. Mar 1999 A
5885467 Zekenák et al. Mar 1999 A
5888611 Leonard Mar 1999 A
5893838 Daoud et al. Apr 1999 A
5922305 Spears Jul 1999 A
5957899 Spears et al. Sep 1999 A
5958377 Spears Sep 1999 A
5976119 Spears et al. Nov 1999 A
6030357 Daoud et al. Feb 2000 A
6071258 Dalke et al. Jun 2000 A
6123698 Spears et al. Sep 2000 A
6142971 Daoud et al. Nov 2000 A
6169117 Spears Jan 2001 B1
6180059 Divino, Jr. et al. Jan 2001 B1
6197279 Spears Mar 2001 B1
6235007 Divino, Jr. et al. May 2001 B1
6238645 Spears May 2001 B1
6248087 Spears et al. Jun 2001 B1
6344483 Hallinan et al. Feb 2002 B1
6346192 Buhr et al. Feb 2002 B2
6413233 Sites et al. Jul 2002 B1
6454997 Divino et al. Sep 2002 B1
Foreign Referenced Citations (16)
Number Date Country
2 343 845 Mar 1974 DE
2649126 May 1978 DE
1506555 Apr 1978 GB
WO 9214404 Sep 1992 WO
WO 9214976 Sep 1992 WO
WO 9513843 May 1995 WO
WO 9601593 Jan 1996 WO
WO 9617565 Jun 1996 WO
WO 9640334 Dec 1996 WO
WO 9641987 Dec 1996 WO
WO 9719713 Jun 1997 WO
WO 9749447 Dec 1997 WO
WO 9816203 Apr 1998 WO
WO 9846340 Oct 1998 WO
WO 9908732 Feb 1999 WO
WO 9908733 Feb 1999 WO
Non-Patent Literature Citations (64)
Entry
Barlett et al., “Instrumentation for cardiopulmonary bypass—past, present, and future,” Medical Instrumentation, vol. 10, No. 2, pp. 119-124, Mar.-Apr. 1976.
Beckley, et al., “Comparison of the performance characteristics of three generations of membrane oxygenators: Univox®, Univox®Gold™ and Spiralgold™,” Perfusion, vol. 11, No. 1, pp. 61-70, 1996.
Boe et al., “Use of Hyperbaric Oxygen as Oxygen Source in Extracorporeal Oxygenation of Blood,” Physiological and Clinical Aspects of Oxygenator Design, Elsevier North-Holland Biomedical Press, Luxembourg, 1976.
Brereton et al., “Nucleation in small capillary tubes,” Chemical Physics 230, pp. 253-265, 1998.
Campbell, Changing Criteria for the Artificial Lung Historic Controls on the Technology of ECMO,: ASAIO Journal, vol. 40, No. 2, pp. 109-120, Apr.-Jun. 1994.
Cason et al., “Therapeutic Hyperoxia Diminishes Myocardial Stunning,” J Card Surg, pp. 459-464, 1994.
Cason, et al., “Effects of High Arterial Oxygen Tension on Function, Blood Flow Distribution, and Metabolism in Ischemic Myocardium,” Circulation, vol. 85, No. 2, pp. 828-838, Feb. 1992.
Davis et al., “Delivery of Oxygen to Cutaneous Tissue Via a Super Saturated Oxygen (SOS) Emulsion,” Journal of Investigative Dermatology, vol. 112, No. 4, p. 632, Apr. 1999.
Dean, “The Formation of Bubbles,” Journal of Applied Physics, vol. 15, pp. 446-451, May, 1944.
Dohi et al., “Development and Clinical Application of a New Membrane Oxygenator Using a Microporous Polysulfone Membrane,” Trans Am Soc Artif Intern Organs, vol. XXVIII, pp. 338-341, 1982.
Drinker et al., “Engineering Aspects of ECMO Technology,” Artificial Organs, vol. 2, No. 1, pp. 6-11, Feb. 1978.
Eberhart et al., “Mathematical and Experimental Methods for Design and Evaluation of Membrane Oxygenators,” Artificial Organs, vol. 2, No. 1, pp. 19-34, Feb. 1978.
Finkelstein et al., “Formation of Gas Bubbles in Supersaturated Solutions of Gases in Water,” AlChE Journal, vol. 13, No. 9, pp. 1409-1419, Sep., 1985.
Fluosol , “Fluosol® 20% Intravascular Perfluorochemical Emulsion Product Information,” Alpha Therapeutic Corporation, Los Angeles, California, pp. 1-8, Dec. 1989.
Fluosol , Product Monograph, Fluosol® 20% Intravascular Perfluorochemical Emulsion, “Delivers Oxygen to Protect the Heart During PTCA,” Alpha Therapeutic Corporation, pp. 3-30.
Fried, et al., “Clinical oxygen transfer comparison of the Terumo Capiox SX18 and SX25 membrane oxygenators,” Perfusion, vol. 13, No. 2, pp. 119-127, 1998.
Gaylor et al., “Membrane oxygenators: influence of design on performance,” Perfusion, vol. 9, No. 3, pp. 173-180, 1994.
Gerth et al., “Gas Supersaturation Thresholds for Spontaneous Cavitation in Water with Gas Equilibration Pressures up to 570 atml,” Z. Naturforsch, 31a, pp. 1711-1716, Oct. 5, 1976.
Guttikonda et al. “Effect of Topical O2-Supersaturated Normal Saline on UV Light-Induced Mouse Ear Inflammation,” SSID Dermatology Session Abstract, vol. 44, No. 1, p. 51A, Jan. 1996.
Harvey et al., “Bubble Formation In Animals,” J. Cell. Comp. Physiol., vol. 24, pp. 23-34.
Hemmingsen, “Cavitation in gas-supersaturated solutions,” Journal of Applied Physics, vol. 46, No. 1, pp. 213-218, Jan. 1976.
Hemmingsen, “Effects of Surfactants and Electrolytes on the Nucleation of Bubbles in Gas-Supersaturated Solutions,” Z. Naturforsch, 33a, pp. 164-171, Oct. 25, 1977.
Henney et al., “Post MI Aqueous Oxygen Hyperoxemic Coronary Reperfusion Acutely Improves Canine LV Function Compared to Normoxemic Reperfusion,” (Abstract/Poster TCT-277), Amer. J. Cardiology, p. 100S, Oct. 8, 1998.
High et al., “Polysulfone Coating for Hollow Fiber Artificial Lungs Operated at Hypobaric and Hyperbaric Pressures,” ASAIO Journal, vol. 42, No. 5, pp. M442-M445, Sep.-Oct. 1996.
Kantor et al., “Coronary Reperfusion with Aqueous Oxygen Improves Left Ventricular Ejection Fraction and May Reduce Mortality in an Ischemic Porcine Model,” (Abstracts/Poster TCT-231), Amer. J. Cardiology, p. 86S, Oct. 8, 1998.
Karlson et al., “Initial Clinical Experience With a Low Pressure Drop Membrane Oxygenator for Cardiopulmonary Bypass in Adult Patients,” The American Journal of Surgery, vol. 147, pp. 447-450, Apr. 1984.
Karlson et al., “Total cardiopulmonary bypass with a new microporous Teflon membrane oxygenator,” Surgery,vol. 76, No. 6, pp. 935-945, Dec. 1974.
Kawamura et al., “ECMO in pumpless RV to LA bypass,” Trans Am Soc Artif Intern Organs, vol. XXXI, pp. 616-621, 1985.
Kenrick et al., “Supersaturation of Gases in Liquids,” J. Phys. Chem., vol. 28, pp. 1308-1315, 1924.
Lefemine et al., “Increased oxygen pressure to improve the efficiency of membrane oxygenators,” Medical Instrumentation, vol. 10, No. 6, pp. 304-308, Nov.-Dec. 1976.
Maas et al., “Superoxygenation Process Treats Highly Concentrated Wastewaters,” Water/Engineering & Management, pp. 29-33, 39, Feb. 1997.
Marlow et al., “A pO2 Regulation System For Membrane Oxygenators,” American Society For Artificial Internal Organs, vol. XXVII, pp. 299-303, 1981.
Matsuda et al., “Evaluation of a New Siliconized Polypropylene Hollow Fiber Membrane Lung for ECMO,” Trans Am Soc Artif Intern Organs, vol. XXXI, pp. 599-603, 1985.
Metschl, “The Supersaturation of Gases in Water and Certain Organic Liquids,” vol. 28, pp. 417-437, 1924.
Mieszala et al., “Evaluation of a New Low Pressure Drop Membrane Oxygenator,” Trans Am Soc Artif Intern Organs, vol. XXVIII, pp. 342-349, 1982.
Minami et al., “Pulsatile and nonpulsatile extracorporeal circulation using Capiox®E Terumo oxygenator: a comparison study with Ultrox® and Maxima® membrane oxygenators,” The Journal of Cardiovascular Surgery, vol. 38, No. 3, pp. 227-232, Jun. 1997.
Niimi et al, “Effects of Ultrathin Silicone Coating of Porous Membrane on Gas Transfer and Hemolytic Performance,” Artificial Organs, vol. 21, No. 10, pp. 1082-1086, Oct. 1997.
Ohtake et al., “Experimental Evaluation of Pumpless Arteriovenous ECMO With Polypropylene Hollow Fiber Membrane Oxygenator for Partial Respiratory Support,” Trans Am Soc Artif Intern Organs, vol. XXIX, pp. 237-241, 1983.
Rubin et al., “Measurments of Critical Supersaturation for Homogeneous Nucleation of Bubbles,” American Chemical Society, Dec. 9, 1986.
Servas et al., “High Efficiency Membrane Oxygenator,” Trans Am Soc Artif Intern Organs, vol. XXIX, pp. 231-236, 1983.
Shandling et al., “Hyperbaric oxygen and thrombolysis in myocardial infarction: The “HOT MI” Pilot Study,” American Heart Journal, vol. 134, No. 3, pp. 544-550, Sep. 1997.
Snider et al., Small Intrapulmonary Artery Lung Prototypes: Design, Construction, and In Vitro Water Testing, ASAIO Journal, pp. M533-M539, 1994.
Spears et al. Aqueous Oxygen: A Highly O2-Supersaturated Infusate for Hyperoxemic Treatment of Postischemic Myocardium, (Abstract/Poster TCT-262), The American Journal of Cardiology, Sep. 1997.
Spears et al., “Aqueous Oxygen—A Highly O2-Supersaturated Infusate for Regional Correction of Hypoxemia and Production of Hyperoxemia,” Circulation, vol. 96, No. 12, pp. 4385-4391, Dec. 16, 1997.
Spears et al., “Hyperoxemic Perfusion with Aqueous Oxygen Improves LV Function During Experimental MI-Reperfusion,” (Abstract 2038), Circulation, vol. 96, Abstracts from the 70th Scientific Sessions, Supplement I, pp. I-364-I-365, 1997.
Spears et al., “Hyperoxemic Reperfusion With Aqueous Oxygen Improves Left Ventricular Function and Microvascular Flow in the Postischemic Canine Myocardium,” (Abstract 1185-127), JACC, vol. 31 (Suppl. A) p. 449A, Feb. 1998.
Spears et al., “Intraaortic Infusion of Oxygen in a Rabbit Model,” (Abstracts/Poster 1014-155), JACC, vol. 29, Suppl. A, pp. 317A-318A, Feb. 1997.
Spears et al., “Myocardial Protection With a Perfusion Guidewire During Ballon Angioplasty in a Canine Model,” (Abstracts/Poster 1032-30), JACC, vol. 27, Suppl. A, p. 392A, Feb. 1996.
Spears et al., “Potential Intravascular Oxygenation with Oxygen Clathrate Hydrate,” (Abstract 388), Abstracts From the 65th Scientific Sessions, Circulation, vol. 80, Suppl. I, p. I-97, 1992.
Spears et al., “Subselective Intracoronary Aqueous Oxygen Hyperoxemic Reperfusion After One Hour Coronary Occlusion in Swine Restores Left Ventricular Function,” (Abstracts/Poster 1124-165), JACC, vol. 33, Suppl. A, p. 357A, Feb. 1999.
Spears, “Advances in the Management of Respiratory Failure—Aqueous Preparations of Oxygen,” American Society for Artificial Internal Organs, Inc., vol. 42, No. 3, May-Jun., 1996.
Spratt et al., “Evaluation of a Membrane Oxygenator For Clinical Cardiopulmonary Bypass,” Trans Am Soc Artif Intern Organs, vol. XXVII, pp. 285-288, 1981.
Stroev et al., “Supersaturated fluorocarbon as an oxygen source,” Physiological and Clinical Aspects of Oxygenator Design, Elsevier North-Holland Biomedical Press, pp. 129-139, Luxembourg, 1976.
Sueda et al., “Evaluation of Two New Liquid-Liquid Oxygenators,” ASAIO Journal, pp. 923-928, 1993.
Tamari et al., “The Effect of High Pressure on Microporous Membrane Oxygenator Failure,” Artificial Organs, vol. 15, No. 1, pp. 15-22, Feb. 1991.
Valdés et al., “Ex Vivo Evaluation of a New Capillary Membrane Oxygenator,” Trans Am Soc Artif Intern Organs, vol. XXVII, pp. 270-275, 1981.
Vaslef, et al., “Design and Evaluation of a New, Low Pressure Loss, Implantable Artificial Lung,” ASAIO Journal, vol. 40, No. 3, pp. M522-M526, Jul.-Sep., 1994.
Yusof et al., “Assessment of the Safety and Efficacy of Supersaturated Oxygen Solution: A Novel Method of Reducing Myocardial Ischaemia in PTCA,”(Abstracts/Poster TCT-276), Amer. J. Cardiology, p. 100S, Oct. 8, 1998.
Zingg et al., “Improving the Efficiency of a Tubular Membrane Oxygenator,” Med. Progr. Technol. 4, pp. 130-145, 1976.
Zwischenberger et al., “Total Respiratory Support With Single Cannula Venovenous ECMO: Double Lumen Continuous Flow vs. Single Lumen Tidal Flow,” Trans Am Soc Artif Intern Organs, vol. XXXI, pp. 610-615, 1985.
U.S. patent application Ser. No. 08/581,019, Spears, filed Jan. 3, 1996, “Stabilized Gas-Enriched and Gas-Supersaturated Liquids”.
U.S. patent application Ser. No. 08/915,532, Spears et al., filed Aug. 15, 1997, “Method for Generalized Extracorporeal Support”.
U.S. patent application Ser. No. 09/122,438, Divino, Jr. et al., filed Jul. 24, 1998, “Apparatus for the Preparation and Delivery of Gas-Supersaturated Fluids”.
U.S. patent application Ser. No. 09/312,181, Buhr et al., filed May 14, 1999, “Apparatus and Method for High Pressure Fluid Filtration”.